{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:09:02Z","timestamp":1792804142709,"version":"4.5.0"},"update-to":[{"DOI":"10.1002\/14651858.cd007784.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T00:00:00Z","timestamp":1701216000000}}],"reference-count":456,"publisher":"Wiley","issue":"12","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd007784.pub3","type":"journal-article","created":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T11:53:50Z","timestamp":1701258830000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis"],"prefix":"10.1002","volume":"2023","author":[{"given":"David J","family":"Tunnicliffe","sequence":"additional","affiliation":[{"name":"Sydney School of Public Health; The University of Sydney; Sydney Australia"},{"name":"Centre for Kidney Research; The Children's Hospital at Westmead; Westmead Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suetonia C","family":"Palmer","sequence":"additional","affiliation":[{"name":"Department of Medicine; University of Otago Christchurch; Christchurch New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brydee A","family":"Cashmore","sequence":"additional","affiliation":[{"name":"Sydney School of Public Health; The University of Sydney; Sydney Australia"},{"name":"Centre for Kidney Research; The Children's Hospital at Westmead; Westmead Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria M","family":"Saglimbene","sequence":"additional","affiliation":[{"name":"Sydney School of Public Health; The University of Sydney; Sydney Australia"},{"name":"Centre for Kidney Research; The Children's Hospital at Westmead; Westmead Australia"},{"name":"Department of Emergency and Organ Transplantation; University of Bari; Bari Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rathika","family":"Krishnasamy","sequence":"additional","affiliation":[{"name":"Renal Unit; Sunshine Coast University Hospital; Birtinya Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Lambert","sequence":"additional","affiliation":[{"name":"School of Medicine; University of Wollongong; Wollongong Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W","family":"Johnson","sequence":"additional","affiliation":[{"name":"Department of Nephrology; Princess Alexandra Hospital; Woolloongabba Australia"},{"name":"Australasian Kidney Trials Network; The University of Queensland; Brisbane Australia"},{"name":"Translational Research Institute; Brisbane Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan C","family":"Craig","sequence":"additional","affiliation":[{"name":"Sydney School of Public Health; The University of Sydney; Sydney Australia"},{"name":"Cochrane Kidney and Transplant, Centre for Kidney Research; The Children's Hospital at Westmead; Westmead Australia"},{"name":"College of Medicine and Public Health; Flinders University; Adelaide Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni FM","family":"Strippoli","sequence":"additional","affiliation":[{"name":"Department of Emergency and Organ Transplantation; University of Bari; Bari Italy"},{"name":"Cochrane Kidney and Transplant, Centre for Kidney Research; The Children's Hospital at Westmead; Westmead Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,11,29]]},"reference":[{"issue":"25","key":"10.1002\/14651858.CD007784.pub3-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1161\/hc5001.100624","article-title":"Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S","volume":"104","author":"Ballantyne","year":"2001","journal-title":"Circulation"},{"issue":"8960","key":"10.1002\/14651858.CD007784.pub3-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S0140-6736(95)90926-5","article-title":"Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S)","volume":"345","year":"1995","journal-title":"Lancet"},{"issue":"5","key":"10.1002\/14651858.CD007784.pub3-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/j.1399-0004.1997.tb04342.x","article-title":"Lp(a) lipoprotein level predicts survival and major coronary events in the Scandinavian Simvastatin Survival Study","volume":"52","author":"Berg","year":"1997","journal-title":"Clinical Genetics"},{"issue":"3","key":"10.1002\/14651858.CD007784.pub3-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1053\/j.ajkd.2006.11.043","article-title":"Simvastatin for secondary prevention of all-cause mortality and major coronary events in patients with mild chronic renal insufficiency","volume":"49","author":"Chonchol","year":"2007","journal-title":"American Journal of Kidney Diseases"},{"issue":"10","key":"10.1002\/14651858.CD007784.pub3-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1002\/clc.4960251005","article-title":"Inflammatory predictors of mortality in the Scandinavian Simvastatin Survival Study","volume":"25","author":"Crea","year":"2002","journal-title":"Clinical Cardiology"},{"issue":"5","key":"10.1002\/14651858.CD007784.pub3-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/0002-9149(93)90438-I","article-title":"Design and baseline results of the Scandinavian Simvastatin Survival Study of patients with stable angina and\/or previous myocardial infarction","volume":"71","year":"1993","journal-title":"American Journal of Cardiology"},{"issue":"10","key":"10.1002\/14651858.CD007784.pub3-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1053\/euhj.1998.1191","article-title":"Differences in the treatment of coronary heart disease between countries as revealed in the Scandinavian Simvastatin Survival Study (4S)","volume":"19","author":"Faergeman","year":"1998","journal-title":"European Heart Journal"},{"issue":"12","key":"10.1002\/14651858.CD007784.pub3-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1161\/01.CIR.101.12.1366","article-title":"The apolipoprotein \u01904 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction: a substudy of the Scandinavian simvastatin survival study","volume":"101","author":"Gerdes","year":"2000","journal-title":"Circulation"},{"issue":"22","key":"10.1002\/14651858.CD007784.pub3-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1001\/archinte.159.22.2661","article-title":"Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study","volume":"159","author":"Haffner","year":"1999","journal-title":"Archives of Internal Medicine"},{"issue":"4","key":"10.1002\/14651858.CD007784.pub3-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2337\/diacare.20.4.469","article-title":"The Scandinavian Simvastatin Survival Study (4S) subgroup analysis of diabetic subjects: implications for the prevention of coronary heart disease","volume":"20","author":"Haffner","year":"1997","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1002\/14651858.CD007784.pub3-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.2337\/diacare.22.11.1771","article-title":"Effect of simvastatin treatment on cardiovascular resource utilization in impaired fasting glucose and diabetes. Findings from the Scandinavian Simvastatin Survival Study","volume":"22","author":"Herman","year":"1999","journal-title":"Diabetes Care"},{"issue":"Abstracts","key":"10.1002\/14651858.CD007784.pub3-BIB0012|cit12","first-page":"98A","article-title":"Effect of simvastatin on kidney function loss in patients with coronary heart disease [abstract no: SU-FC137]","volume":"18","author":"Huskey","year":"2007","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD007784.pub3-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.atherosclerosis.2008.11.010","article-title":"Effect of simvastatin on kidney function loss in patients with coronary heart disease: findings from the Scandinavian Simvastatin Survival Study (4S)","volume":"205","author":"Huskey","year":"2009","journal-title":"Atherosclerosis"},{"issue":"5","key":"10.1002\/14651858.CD007784.pub3-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1056\/NEJM199701303360503","article-title":"Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group","volume":"336","author":"Johannesson","year":"1997","journal-title":"New England Journal of Medicine"},{"issue":"11","key":"10.1002\/14651858.CD007784.pub3-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1007\/s001250051441","article-title":"The cost-effectiveness of lipid lowering in patients with diabetes: results from the 4S trial","volume":"42","author":"Jonsson","year":"1999","journal-title":"Diabetologia"},{"issue":"7","key":"10.1002\/14651858.CD007784.pub3-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1093\/oxfordjournals.eurheartj.a014994","article-title":"Cost-effectiveness of cholesterol lowering. Results from the Scandinavian Simvastatin Survival Study (4S)","volume":"17","author":"J\u00f6nsson","year":"1996","journal-title":"European Heart Journal"},{"issue":"7138","key":"10.1002\/14651858.CD007784.pub3-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1136\/bmj.316.7138.1127","article-title":"Baseline serum cholestanol as predictor of recurrent coronary events in subgroup of Scandinavian simvastatin survival study. Finnish 4S Investigators","volume":"316","author":"Miettinen","year":"1998","journal-title":"BMJ"},{"issue":"1-2","key":"10.1002\/14651858.CD007784.pub3-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.cca.2006.12.011","article-title":"Blood glucose and the metabolism of cholesterol in coronary patients with and without simvastatin treatment","volume":"379","author":"Miettinen","year":"2007","journal-title":"Clinica Chimica Acta"},{"issue":"12","key":"10.1002\/14651858.CD007784.pub3-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"4211","DOI":"10.1161\/01.CIR.96.12.4211","article-title":"Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S)","volume":"96","author":"Miettinen","year":"1997","journal-title":"Circulation"},{"issue":"18","key":"10.1002\/14651858.CD007784.pub3-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1001\/archinte.1996.00440170097011","article-title":"Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study","volume":"156","author":"Pedersen","year":"1996","journal-title":"Archives of Internal Medicine"},{"issue":"3","key":"10.1002\/14651858.CD007784.pub3-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.atherosclerosissup.2004.08.027","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994","volume":"5","author":"Pedersen","year":"2004","journal-title":"Atherosclerosis Supplements"},{"issue":"10","key":"10.1002\/14651858.CD007784.pub3-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1161\/01.CIR.93.10.1796","article-title":"Cholesterol lowering and the use of healthcare resources. Results of the Scandinavian Simvastatin Survival Study. [Erratum appears in Circulation 1996 Aug 15;94(4):849]","volume":"93","author":"Pedersen","year":"1996","journal-title":"Circulation"},{"issue":"3","key":"10.1002\/14651858.CD007784.pub3-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0002-9149(97)00904-1","article-title":"Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S)","volume":"81","author":"Pedersen","year":"1998","journal-title":"American Journal of Cardiology"},{"issue":"15","key":"10.1002\/14651858.CD007784.pub3-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1161\/01.CIR.97.15.1453","article-title":"Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S)","volume":"97","author":"Pedersen","year":"1998","journal-title":"Circulation"},{"issue":"3","key":"10.1002\/14651858.CD007784.pub3-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0002-9149(00)00910-3","article-title":"Follow-up study of patients randomized in the Scandinavian Simvastatin Survival Study (4S) of cholesterol lowering","volume":"86","author":"Pedersen","year":"2000","journal-title":"American Journal of Cardiology"},{"issue":"7","key":"10.1002\/14651858.CD007784.pub3-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.2337\/diacare.27.7.1735","article-title":"Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome: subgroup analyses of the Scandinavian Simvastatin Survival Study (4S)","volume":"27","author":"Pyor\u00e4l\u00e4","year":"2004","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1002\/14651858.CD007784.pub3-BIB0027|cit27","first-page":"614","article-title":"Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S).[Erratum appears in Diabetes Care 1997 Jun;20(6):1048]","volume":"20","author":"Pyor\u00e4l\u00e4","year":"1997","journal-title":"Diabetes Care"},{"issue":"8934","key":"10.1002\/14651858.CD007784.pub3-BIB0028|cit28","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)","volume":"344","year":"1994","journal-title":"Lancet"},{"issue":"9436","key":"10.1002\/14651858.CD007784.pub3-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S0140-6736(04)16936-5","article-title":"Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S)","volume":"364","author":"Strandberg","year":"2004","journal-title":"Lancet"},{"issue":"13","key":"10.1002\/14651858.CD007784.pub3-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1053\/euhj.2000.2481","article-title":"Risk factors for a major coronary event after myocardial infarction in the Scandinavian Simvastatin Survival Study (4S). Impact of predicted risk on the benefit of cholesterol-lowering treatment","volume":"22","author":"Wilhelmsen","year":"2001","journal-title":"European Heart Journal"},{"issue":"11","key":"10.1002\/14651858.CD007784.pub3-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.5551\/jat.9084","article-title":"Effects of lipid-lowering therapy with rosuvastatin on kidney function and oxidative stress in patients with diabetic nephropathy","volume":"18","author":"Abe","year":"2011","journal-title":"Journal of Atherosclerosis & Thrombosis"},{"issue":"12","key":"10.1002\/14651858.CD007784.pub3-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.5551\/jat.29264","article-title":"A trial of pitavastatin versus rosuvastatin for dyslipidemia in chronic kidney disease","volume":"22","author":"Abe","year":"2015","journal-title":"Journal of Atherosclerosis & Thrombosis"},{"issue":"10","key":"10.1002\/14651858.CD007784.pub3-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1089\/152460901317193549","article-title":"Air Force\/Texas Coronary Atherosclerosis Prevention Study (AFCAPS\/TexCAPS): efficacy and tolerability of long-term treatment with lovastatin in women","volume":"10","author":"Clearfield","year":"2001","journal-title":"Journal of Womens Health & Gender-Based Medicine"},{"issue":"2","key":"10.1002\/14651858.CD007784.pub3-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1177\/204748730000700207","article-title":"Air Force\/Texas Coronary Atherosclerosis Prevention Study (AFCAPS\/TexCAPS): baseline characteristics and comparison with USA population","volume":"7","author":"Clearfield","year":"2000","journal-title":"Journal of Cardiovascular Risk"},{"issue":"7","key":"10.1002\/14651858.CD007784.pub3-BIB0035|cit35","first-page":"377","article-title":"Lability of serum low-density lipoprotein cholesterol levels during screening in subgroup of Air Force\/Texas Coronary Atherosclerosis Prevention Study (AFCAPS\/TexCAPS) cohort","volume":"102","author":"Clearfield","year":"2002","journal-title":"Journal of the American Osteopathic Association"},{"issue":"6","key":"10.1002\/14651858.CD007784.pub3-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.amjcard.2009.05.020","article-title":"Effects of increasing high-density lipoprotein cholesterol and decreasing low-density lipoprotein cholesterol on the incidence of first acute coronary events (from the Air Force\/Texas Coronary Atherosclerosis Prevention Study)","volume":"104","author":"Cui","year":"2009","journal-title":"American Journal of Cardiology"},{"issue":"3","key":"10.1002\/14651858.CD007784.pub3-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S0002-9149(97)00347-0","article-title":"Design & rationale of the Air Force\/Texas Coronary Atherosclerosis Prevention Study (AFCAPS\/TexCAPS)","volume":"80","author":"Downs","year":"1997","journal-title":"American Journal of Cardiology"},{"issue":"9","key":"10.1002\/14651858.CD007784.pub3-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/S0002-9149(01)01464-3","article-title":"Air Force\/Texas Coronary Atherosclerosis Prevention Study (AFCAPS\/TEXCAPS): additional perspectives on tolerability of long-term treatment with lovastatin","volume":"87","author":"Downs","year":"2001","journal-title":"American Journal of Cardiology"},{"issue":"20","key":"10.1002\/14651858.CD007784.pub3-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","article-title":"Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS\/TexCAPS. Air Force\/Texas Coronary Atherosclerosis Prevention Study","volume":"279","author":"Downs","year":"1998","journal-title":"JAMA"},{"issue":"11","key":"10.1002\/14651858.CD007784.pub3-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1016\/S0002-9149(00)01198-X","article-title":"Effect of lovastatin on cardiovascular resource utilization and costs in the Air Force\/Texas Coronary Atherosclerosis Prevention Study (AFCAPS\/TexCAPS). AFCAPS\/TexCAPS Research Group","volume":"86","author":"Boccuzzi","year":"2000","journal-title":"American Journal of Cardiology"},{"issue":"1","key":"10.1002\/14651858.CD007784.pub3-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1053\/j.ajkd.2009.09.020","article-title":"Effect of lovastatin on primary prevention of cardiovascular events in mild CKD and kidney function loss: a post hoc analysis of the Air Force\/Texas Coronary Atherosclerosis Prevention Study","volume":"55","author":"Kendrick","year":"2010","journal-title":"American Journal of Kidney Diseases"},{"issue":"2","key":"10.1002\/14651858.CD007784.pub3-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S0002-9149(00)00872-9","article-title":"Aggressive Lipid-Lowering Initiation Abates New Cardiac Events (ALLIANCE)-rationale and design of atorvastatin versus usual care in hypercholesterolemic patients with coronary artery disease","volume":"86","author":"Isaacsohn","year":"2000","journal-title":"American Journal of Cardiology"},{"issue":"5","key":"10.1002\/14651858.CD007784.pub3-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1053\/j.ajkd.2008.11.025","article-title":"Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD","volume":"53","author":"Koren","year":"2009","journal-title":"American Journal of Kidney Diseases"},{"key":"10.1002\/14651858.CD007784.pub3-BIB0044|cit44","unstructured":"Koren MJ Davidson MH Aggressive treatment with atorvastatin is associated with improvement in renal function in managed care patients with coronary heart disease: the ALLIANCE study [abstract no: S-FC-018] 4th World Congress of Nephrology. 19th International Congress of the International Society of Nephrology (ISN); 2007 Apr 21-25; Rio de Janeiro, Brazil 2007 44"},{"issue":"9","key":"10.1002\/14651858.CD007784.pub3-BIB0045|cit45","first-page":"1772","article-title":"Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the ALLIANCE study","volume":"44","author":"Koren","year":"2004","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1002\/14651858.CD007784.pub3-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1016\/j.clinthera.2008.12.007","article-title":"Cost-effectiveness of intensive atorvastatin treatment in high-risk patients compared with usual care in a postgeneric statin market: economic analysis of the Aggressive Lipid-lowering Initiation Abates New Cardiac Events (ALLIANCE) study","volume":"30 Pt 2","author":"Mullins","year":"2008","journal-title":"Clinical Therapeutics"},{"issue":"11","key":"10.1002\/14651858.CD007784.pub3-BIB0047|cit47","first-page":"523","article-title":"Effect of pravastatin on hypercholesterolemia associated with proteinuria","volume":"11","author":"Aranda Arcas","year":"1994","journal-title":"Anales de Medicina Interna"},{"key":"10.1002\/14651858.CD007784.pub3-BIB0048|cit48","unstructured":"Gupta A Chang C Collier D Dahlof B Poulter N Sever P The relationship between statin therapy and progression of renal damage among 10305 hypertensive patients randomised in the ASCOT-lipid-lowering arm (LLA) [abstract no: O86] British Renal Society Conference; 2013 May 14-May 16; Manchester, UK 2013"},{"key":"10.1002\/14651858.CD007784.pub3-BIB0049|cit49","doi-asserted-by":"crossref","unstructured":"Gupta A Chang C Collier D Dahlof B Poulter N Sever P The relationship between statin therapy and progression of renal damage among 10305 hypertensive patients randomised in the ASCOT-lipid-lowering arm (LLA) [abstract] Renal Association & British Renal Society Joint Meeting; 2011 Jun 6-9 ; Birmingham, UK 2011 1043","DOI":"10.1016\/S1567-5688(11)70759-0"},{"issue":"1","key":"10.1002\/14651858.CD007784.pub3-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S1567-5688(11)70759-0","article-title":"The relationship between statin therapy and progression of renal damage among 10305 hypertensive patients randomised in the Ascot-Lipid-Lowering Arm (LLA) [abstract]","volume":"12","author":"Gupta","year":"2011","journal-title":"Atherosclerosis Supplements"},{"issue":"10","key":"10.1002\/14651858.CD007784.pub3-BIB0051|cit51","first-page":"633","article-title":"Cardiovascular and all-cause mortality outcomes among hypertensive patients with moderate renal dysfunction in the ASCOT-LLA, and its extended follow-up [abstract no: 5A.1]","volume":"25","author":"Gupta","year":"2011","journal-title":"Journal of Human Hypertension"},{"key":"10.1002\/14651858.CD007784.pub3-BIB0052|cit52","first-page":"220","article-title":"Cardiovascular and all-cause mortality outcomes among hypertensive patients with moderate renal dysfunction in the ASCOT-LLA, and its extended follow-up [abstract no: P1480]","volume":"32","author":"Gupta","year":"2011","journal-title":"European Heart Journal"},{"issue":"1","key":"10.1002\/14651858.CD007784.pub3-BIB0053|cit53","first-page":"29","article-title":"Cost-effectiveness of atorvastatin for the prevention of coronary and stroke events: an economic analysis of the Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA)","volume":"12","author":"Lindgren","year":"2005","journal-title":"European Journal of Cardiovascular Prevention & Rehabilitation"},{"issue":"20","key":"10.1002\/14651858.CD007784.pub3-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1093\/eurheartj\/ehr333","article-title":"The Anglo-Scandinavian Cardiac Outcomes Trial: 11-year mortality follow-up of the lipid-lowering arm in the U.K","volume":"32","author":"Sever","year":"2011","journal-title":"European Heart Journal"},{"key":"10.1002\/14651858.CD007784.pub3-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2165\/00003495-200464002-00005","article-title":"Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial","volume":"64 Suppl 2","author":"Sever","year":"2004","journal-title":"Drugs"},{"issue":"9364","key":"10.1002\/14651858.CD007784.pub3-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","article-title":"Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial","volume":"361","author":"Sever","year":"2003","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD007784.pub3-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/eurheartj\/ehm583","article-title":"The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm: extended observations 2 years after trial closure","volume":"29","author":"Sever","year":"2008","journal-title":"European Heart Journal"},{"issue":"5","key":"10.1002\/14651858.CD007784.pub3-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.2337\/diacare.28.5.1151","article-title":"Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA)","volume":"28","author":"Sever","year":"2005","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1002\/14651858.CD007784.pub3-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1097\/HJH.0b013e328326cb1a","article-title":"Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension","volume":"27","author":"Sever","year":"2009","journal-title":"Journal of Hypertension"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD007784.pub3-BIB0060|cit60","first-page":"413A","article-title":"Effects of atorvastatin on renal function in patients with dyslipidemia and chronic kidney disease: design of the ASsessment of clinial usefulness in CKD patients with atorvastatin (ASUCA) trial [abstract no: FR-PO194]","volume":"23","author":"Kasahara","year":"2012","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD007784.pub3-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s10157-016-1304-6","article-title":"Effects of atorvastatin on renal function in patients with dyslipidemia and chronic kidney disease: assessment of clinical usefulness in CKD patients with atorvastatin (ASUCA) trial","volume":"21","author":"Kimura","year":"2017","journal-title":"Clinical & Experimental Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD007784.pub3-BIB0062|cit62","first-page":"5B","article-title":"Effects of atorvastatin on renal function in patients with dyslipidemia and chronic kidney disease: ASsessment of clinical usefulness in CKD patients with atorvastatin (ASUCA) trial [abstract no: SA-O1086]","volume":"24","author":"Kimura","year":"2013","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD007784.pub3-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"iii482","DOI":"10.1093\/ndt\/gfx164.MP147","article-title":"The association between the control of LDL-cholesterol level and renal function in CKD patients with hyperlipidemia [abstract no: MP147]","volume":"32","author":"Kuwabara","year":"2017","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"5","key":"10.1002\/14651858.CD007784.pub3-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1007\/s10157-019-01840-4","article-title":"The association between uric acid levels and renal function of CKD patients with hyperlipidemia: a sub-analysis of the ASUCA trial","volume":"24","author":"Kuwabara","year":"2020","journal-title":"Clinical & Experimental Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD007784.pub3-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s10157-012-0676-5","article-title":"Effects of atorvastatin on renal function in patients with dyslipidemia and chronic kidney disease: rationale and design of the ASsessment of clinical Usefulness in CKD patients with Atorvastatin (ASUCA) trial","volume":"17","author":"Ueshima","year":"2013","journal-title":"Clinical & Experimental Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD007784.pub3-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1053\/ajkd.2003.50140","article-title":"A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease [Erratum in: Am J Kidney Dis. 2004 Jan;43(1):193]","volume":"41","author":"Bianchi","year":"2003","journal-title":"American Journal of Kidney Diseases"},{"issue":"4","key":"10.1002\/14651858.CD007784.pub3-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1067\/mcp.2000.105330","article-title":"Effect of fluvastatin on proteinuria in patients with immunoglobulin A nephropathy","volume":"67","author":"Buemi","year":"2000","journal-title":"Clinical Pharmacology & Therapeutics"},{"issue":"5","key":"10.1002\/14651858.CD007784.pub3-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1053\/j.ajkd.2009.03.022","article-title":"Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS)","volume":"54","author":"Colhoun","year":"2009","journal-title":"American Journal of Kidney Diseases"},{"issue":"9435","key":"10.1002\/14651858.CD007784.pub3-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","article-title":"Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial","volume":"364","author":"Colhoun","year":"2004","journal-title":"Lancet"},{"issue":"12","key":"10.1002\/14651858.CD007784.pub3-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1007\/s00125-005-0029-y","article-title":"Rapid emergence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS)","volume":"48","author":"Colhoun","year":"2005","journal-title":"Diabetologia"},{"issue":"12","key":"10.1002\/14651858.CD007784.pub3-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1111\/j.1464-5491.2007.02268.x","article-title":"Stroke prediction and stroke prevention with atorvastatin in the Collaborative Atorvastatin Diabetes Study (CARDS)","volume":"24","author":"Hitman","year":"2007","journal-title":"Diabetic Medicine"},{"issue":"11","key":"10.1002\/14651858.CD007784.pub3-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.2337\/dc06-0872","article-title":"Analysis of efficacy and safety in patients aged 65-75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS)","volume":"29","author":"Neil","year":"2006","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1002\/14651858.CD007784.pub3-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3132\/dvdr.2008.029","article-title":"The safety and tolerability of atorvastatin 10 mg in the Collaborative Atorvastatin Diabetes Study (CARDS)","volume":"5","author":"Newman","year":"2008","journal-title":"Diabetes & Vascular Disease Research"},{"issue":"4","key":"10.1002\/14651858.CD007784.pub3-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00125-006-0561-4","article-title":"Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes: results from the Collaborative Atorvastatin Diabetes Study (CARDS)","volume":"50","author":"Raikou","year":"2007","journal-title":"Diabetologia"},{"issue":"2","key":"10.1002\/14651858.CD007784.pub3-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0021-9150(02)00428-8","article-title":"The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease","volume":"167","author":"Soedamah-Muthu","year":"2003","journal-title":"Atherosclerosis"},{"issue":"8","key":"10.1002\/14651858.CD007784.pub3-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1111\/j.1464-5491.2004.01401.x","article-title":"Baseline characteristics in the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with Type 2 diabetes","volume":"21","author":"Thomason","year":"2004","journal-title":"Diabetic Medicine"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD007784.pub3-BIB0077|cit77","first-page":"239a","article-title":"Effect of fluvastatin treatment on proteinuria in diabetic patients with chronic kidney disease [abstract no: TH-PO656]","volume":"26","author":"Cha","year":"2015","journal-title":"Journal of the American Society of Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD007784.pub3-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/BF02849954","article-title":"Effects of fluvastatin treatment on lipid profile, C-reactive protein trend, and renal function in dyslipidemic patients with chronic renal failure","volume":"22","author":"Di Lullo","year":"2005","journal-title":"Advances in Therapy"},{"key":"10.1002\/14651858.CD007784.pub3-BIB0079|cit79","unstructured":"Di Lullo L Polito P Effects of fluvastatin treatment on lipid profile, inflammatory status and renal function in dyslipidemic patients with chronic renal failure [abstract no: S-PO-0543] 4th World Congress of Nephrology.19th International Congress of the International Society of Nephrology (ISN); 2007 Apr 21-25; Rio de Janeiro, Brazil 2007 195"},{"issue":"6","key":"10.1002\/14651858.CD007784.pub3-BIB0080|cit80","first-page":"900","article-title":"Acute effect of simvastatin on inflammation and oxidative stress in chronic kidney disease","volume":"21","author":"Dummer","year":"2008","journal-title":"Journal of Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD007784.pub3-BIB0081|cit81","first-page":"389A","article-title":"Effects of add-on fluvastatin therapy in patients with chronic proteinuric nephropathy on dual RAS blockade: esplanade trial [abstract no: F-PO1221]","volume":"21","author":"Remuzzi","year":"2010","journal-title":"Journal of the American Society of Nephrology"},{"issue":"11","key":"10.1002\/14651858.CD007784.pub3-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.2215\/CJN.03380410","article-title":"Effects of add-on fluvastatin therapy in patients with chronic proteinuric nephropathy on dual renin-angiotensin system blockade: the ESPLANADE Trial","volume":"5","author":"Ruggenenti","year":"2010","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"1","key":"10.1002\/14651858.CD007784.pub3-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3109\/00365590903359908","article-title":"Effect of pravastatin on kidney function and urinary protein excretion in autosomal dominant polycystic kidney disease","volume":"44","author":"Fassett","year":"2010","journal-title":"Scandinavian Journal of Urology & Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD007784.pub3-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S1056-8727(01)00140-4","article-title":"Lipid modulation in insulin-dependent diabetes mellitus: effect on microvascular outcomes","volume":"15","author":"Fried","year":"2001","journal-title":"Journal of Diabetes & its Complications"},{"key":"10.1002\/14651858.CD007784.pub3-BIB0085|cit85","unstructured":"Gheith O Saad M Sobh M Nephrotic dyslipidemia, harvest of treatment [abstract no: MP085] 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal 2004 258"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD007784.pub3-BIB0086|cit86","first-page":"100","article-title":"Study the effect of treatment of nephrotic dyslipidemia on renal function, fat deposits and scarring in patients with persistent nephrotic syndrome [abstract no: M182]","volume":"17","author":"Gheith","year":"2002","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD007784.pub3-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1159\/000065021","article-title":"Impact of treatment of dyslipidemia on renal function, fat deposits and scarring in patients with persistent nephrotic syndrome","volume":"91","author":"Gheith","year":"2002","journal-title":"Nephron"},{"issue":"12 Suppl 3","key":"10.1002\/14651858.CD007784.pub3-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"S231","DOI":"10.1681\/ASN.2006080938","article-title":"Effects of atorvastatin on inflammatory and fibrinolytic parameters in patients with chronic kidney disease","volume":"17","author":"Goicoechea","year":"2006","journal-title":"Journal of the American Society of Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD007784.pub3-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/BF02342442","article-title":"Plasma lipoproteins and renal function during simvastatin treatment in diabetic nephropathy","volume":"35","author":"Hommel","year":"1992","journal-title":"Diabetologia"},{"issue":"9374","key":"10.1002\/14651858.CD007784.pub3-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(03)13636-7","article-title":"MRC\/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial","volume":"361","author":"Collins","year":"2003","journal-title":"Lancet"},{"issue":"9411","key":"10.1002\/14651858.CD007784.pub3-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(04)15690-0","article-title":"Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions","volume":"363","author":"Collins","year":"2004","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD007784.pub3-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.jacc.2006.08.052","article-title":"N-terminal Pro-B-type natriuretic peptide, vascular disease risk, and cholesterol reduction among 20,536 patients in the MRC\/BHF heart protection study","volume":"49","author":"Emberson","year":"2007","journal-title":"Journal of the American College of Cardiology"},{"issue":"9326","key":"10.1002\/14651858.CD007784.pub3-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0140-6736(02)09328-5","article-title":"MRC\/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","year":"2002","journal-title":"Lancet"},{"issue":"9326","key":"10.1002\/14651858.CD007784.pub3-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","year":"2002","journal-title":"Lancet"},{"issue":"9473","key":"10.1002\/14651858.CD007784.pub3-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/S0140-6736(05)63014-0","article-title":"Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20,536 individuals","volume":"365","author":"Mihaylova","year":"2005","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD007784.pub3-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jvs.2006.12.054","article-title":"Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions","volume":"45","year":"2007","journal-title":"Journal of Vascular Surgery"},{"key":"10.1002\/14651858.CD007784.pub3-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1741-7015-3-6","article-title":"The effects of cholesterol lowering with simvastatin on cause-specific mortality and on cancer incidence in 20,536 high-risk people: a randomised placebo-controlled trial [ISRCTN48489393]","volume":"3","year":"2005","journal-title":"BMC Medicine"},{"issue":"6","key":"10.1002\/14651858.CD007784.pub3-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1080\/07853890801964955","article-title":"Lipoprotein predictors of cardiovascular events in statin-treated patients with coronary heart disease. Insights from the Incremental Decrease In End-points Through Aggressive Lipid-lowering Trial (IDEAL)","volume":"40","author":"Holme","year":"2008","journal-title":"Annals of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD007784.pub3-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/j.1365-2796.2009.02176.x","article-title":"Cardiovascular outcomes and their relationships to lipoprotein components in patients with and without chronic kidney disease: results from the IDEAL trial","volume":"267","author":"Holme","year":"2010","journal-title":"Journal of Internal Medicine"},{"issue":"23","key":"10.1002\/14651858.CD007784.pub3-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1161\/CIRCULATIONAHA.107.713438","article-title":"Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment","volume":"117","author":"Kastelein","year":"2008","journal-title":"Circulation"},{"issue":"6","key":"10.1002\/14651858.CD007784.pub3-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.amjcard.2004.06.003","article-title":"Design and baseline characteristics of the Incremental Decrease in End Points through Aggressive Lipid Lowering study","volume":"94","author":"Pedersen","year":"2004","journal-title":"American Journal of Cardiology"},{"issue":"19","key":"10.1002\/14651858.CD007784.pub3-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1001\/jama.294.19.2437","article-title":"High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial [Erratum appears in JAMA. 2005 Dec 28;294(24):3092]","volume":"294","author":"Pedersen","year":"2005","journal-title":"JAMA"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD007784.pub3-BIB0103|cit103","first-page":"699A","article-title":"Rosuvastatin reduces urinary protein excretion in patients with chronic glomerulonephritis compared to the pravastatin use: a crossover trial [abstract no: SA-PO274]","volume":"23","author":"Ikeda","year":"2012","journal-title":"Journal of the American Society of Nephrology"},{"issue":"8","key":"10.1002\/14651858.CD007784.pub3-BIB0104|cit104","first-page":"1345","article-title":"The effect of pravastatin on renal function and lipid metabolism in patients with renal dysfunction with hypertension and hyperlipidemia. Pravastatin and Renal Function Research Group","volume":"21","author":"Imai","year":"1999","journal-title":"Clinical & Experimental Hypertension (New York)"},{"issue":"7","key":"10.1002\/14651858.CD007784.pub3-BIB0105|cit105","first-page":"947","article-title":"Combination therapy with angiotensin receptor blocker (ARB) plus atorvastatin reduced proteinuria in type 2 diabetic patients with diabetic nephropathy","volume":"32","author":"Inukai","year":"2011","journal-title":"Therapeutic Research"},{"issue":"18","key":"10.1002\/14651858.CD007784.pub3-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1056\/NEJMoa0900241","article-title":"A randomized trial of rosuvastatin in the prevention of venous thromboembolism","volume":"360","author":"Glynn","year":"2009","journal-title":"New England Journal of Medicine"},{"issue":"21","key":"10.1002\/14651858.CD007784.pub3-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"New England Journal of Medicine"},{"issue":"11","key":"10.1002\/14651858.CD007784.pub3-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1016\/j.amjcard.2007.09.072","article-title":"Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein","volume":"100","author":"Ridker","year":"2007","journal-title":"American Journal of Cardiology"},{"issue":"12","key":"10.1002\/14651858.CD007784.pub3-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.jacc.2010.01.020","article-title":"Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evaluating Rosuvastatin) trial","volume":"55","author":"Ridker","year":"2010","journal-title":"Journal of the American College of Cardiology"},{"issue":"7","key":"10.1002\/14651858.CD007784.pub3-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/j.1463-1326.2012.01566.x","article-title":"Randomized comparison of pitavastatin and pravastatin treatment on the reduction of urinary albumin in patients with type 2 diabetic nephropathy","volume":"14","author":"Kimura","year":"2012","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"5","key":"10.1002\/14651858.CD007784.pub3-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1007\/BF00400731","article-title":"Cholesterol-lowering therapy may retard the progression of diabetic nephropathy","volume":"38","author":"Lam","year":"1995","journal-title":"Diabetologia"},{"issue":"3","key":"10.1002\/14651858.CD007784.pub3-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/BF00418356","article-title":"Cholesterol-lowering therapy may retard the progression of diabetic nephropathy","volume":"39","author":"Parving","year":"1996","journal-title":"Diabetologia"},{"issue":"2","key":"10.1002\/14651858.CD007784.pub3-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/j.1523-1755.2005.00457.x","article-title":"Add-on and withdrawal effect of pravastatin on proteinuria in hypertensive patients treated with AT receptor blockers","volume":"68","author":"Lee","year":"2005","journal-title":"Kidney International"},{"issue":"1","key":"10.1002\/14651858.CD007784.pub3-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1161\/01.HYP.0000022805.11288.7F","article-title":"Effect of pravastatin on proteinuria in patients with well-controlled hypertension","volume":"40","author":"Lee","year":"2002","journal-title":"Hypertension"},{"issue":"2","key":"10.1002\/14651858.CD007784.pub3-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0002-9149(05)80027-X","article-title":"Fluvastatin for dyslipoproteinemia, with or without concomitant chronic renal insufficiency","volume":"76","author":"Lintott","year":"1995","journal-title":"American Journal of Cardiology"},{"issue":"2","key":"10.1002\/14651858.CD007784.pub3-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ahj.2004.03.067","article-title":"Fluvastatin reduces the impact of diabetes on long-term outcome after coronary intervention--a Lescol Intervention Prevention Study (LIPS) substudy","volume":"149","author":"Arampatzis","year":"2005","journal-title":"American Heart Journal"},{"issue":"4","key":"10.1002\/14651858.CD007784.pub3-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.amjcard.2004.10.008","article-title":"Long-term fluvastatin reduces the hazardous effect of renal impairment on four-year atherosclerotic outcomes (a LIPS substudy)","volume":"95","author":"Lemos","year":"2005","journal-title":"American Journal of Cardiology"},{"issue":"4","key":"10.1002\/14651858.CD007784.pub3-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1080\/14628840127765","article-title":"The Lescol(R) Intervention Prevention Study (LIPS): a double-blind, placebo-controlled, randomized trial of the long-term effects of fluvastatin after successful transcatheter therapy in patients with coronary heart disease","volume":"4","author":"Serruys","year":"2001","journal-title":"International Journal of Cardiovascular Interventions"},{"issue":"24","key":"10.1002\/14651858.CD007784.pub3-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1001\/jama.287.24.3215","article-title":"Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial","volume":"287","author":"Serruys","year":"2002","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD007784.pub3-BIB0120|cit120","unstructured":"Fassett R Robertson I Ball M Geraghty D Sharman J Coombes J A randomised trial assessing the effects of atorvastatin on arterial stiffness in chronic kidney disease [abstract no: SU193] World Congress of Nephrology; 2009 May 22-26; Milan, Italy 2009"},{"issue":"Abstracts Issue","key":"10.1002\/14651858.CD007784.pub3-BIB0121|cit121","first-page":"543A","article-title":"Atorvastatin and the progression of chronic kidney disease: the LORD Trial [abstract no: F-PO1919]","volume":"19","author":"Fassett","year":"2008","journal-title":"Journal of the American Society of Nephrology"},{"issue":"11","key":"10.1002\/14651858.CD007784.pub3-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"580","DOI":"10.5414\/CPP44580","article-title":"Baseline serum lipids and renal function in chronic kidney disease patients entering the LORD trial","volume":"44","author":"Fassett","year":"2006","journal-title":"International Journal of Clinical Pharmacology & Therapeutics"},{"key":"10.1002\/14651858.CD007784.pub3-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1471-2369-9-4","article-title":"The Lipid lowering and Onset of Renal Disease (LORD) Trial: a randomized double blind placebo controlled trial assessing the effect of atorvastatin on the progression of kidney disease","volume":"9","author":"Fassett","year":"2008","journal-title":"BMC Nephrology"},{"issue":"Nov","key":"10.1002\/14651858.CD007784.pub3-BIB0124|cit124","first-page":"768A","article-title":"Enrolment in a clinical trial improves renal function [abstract no: SU-PO1057]","volume":"14","author":"Fassett","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD007784.pub3-BIB0125|cit125","first-page":"917A","article-title":"Lipid lowering therapy and cognitive function in patients with chronic kidney disease [abstract no: PUB623]","volume":"16","author":"Fassett","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD007784.pub3-BIB0126|cit126","first-page":"158A","article-title":"Atorvastatin slows the progression of chronic kidney disease in patients with inflammation [abstract no: TH-PO204]","volume":"22","author":"Fassett","year":"2011","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD007784.pub3-BIB0127|cit127","first-page":"432A","article-title":"Relationships between physical activity and nutrition with kidney function in CKD patients [abstract no: FR-PO1383]","volume":"22","author":"Fassett","year":"2011","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD007784.pub3-BIB0128|cit128","first-page":"680A","article-title":"Relationships between physical activity and nutrition with quality of life in CKD patients [abstract no: SA-PO2441]","volume":"22","author":"Fassett","year":"2011","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD007784.pub3-BIB0129|cit129","first-page":"641A","article-title":"Effect of atorvastatin on NGAL and cystatin C in chronic kidney disease: a post-hoc analysis of the LORD trial [abstract no: SA-PO2320]","volume":"21","author":"Fassett","year":"2010","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD007784.pub3-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1093\/ndt\/gfr193","article-title":"Effects of atorvastatin on NGAL and cystatin C in chronic kidney disease: a post hoc analysis of the LORD trial","volume":"27","author":"Fassett","year":"2012","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD007784.pub3-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.atherosclerosis.2010.07.053","article-title":"Effect of atorvastatin on kidney function in chronic kidney disease: a randomised double-blind placebo-controlled trial","volume":"213","author":"Fassett","year":"2010","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1002\/14651858.CD007784.pub3-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"75","DOI":"10.5414\/CN108090","article-title":"Effects of atorvastatin on biomarkers of inflammation in chronic kidney disease","volume":"81","author":"Fassett","year":"2014","journal-title":"Clinical Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD007784.pub3-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"235","DOI":"10.5551\/jat.2683","article-title":"Effects of atorvastatin on arterial stiffness in chronic kidney disease: a randomised controlled trial","volume":"17","author":"Fassett","year":"2010","journal-title":"Journal of Atherosclerosis & Thrombosis"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD007784.pub3-BIB0134|cit134","first-page":"40","article-title":"Atorvastatin slows the progression of CKD in patients with inflammation [abstract no: 066]","volume":"16","author":"Fassett","year":"2011","journal-title":"Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD007784.pub3-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1249\/MSS.0b013e3181940aef","article-title":"Physical activity levels in patients with chronic kidney disease entering the LORD trial","volume":"41","author":"Fassett","year":"2009","journal-title":"Medicine & Science in Sports & Exercise"},{"issue":"4","key":"10.1002\/14651858.CD007784.pub3-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1053\/j.jrn.2007.04.004","article-title":"Dietary intake of patients with chronic kidney disease entering the LORD trial: adjusting for underreporting","volume":"17","author":"Fassett","year":"2007","journal-title":"Journal of Renal Nutrition"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD007784.pub3-BIB0137|cit137","first-page":"41","article-title":"Atorvastatin improves kidney function in chronic kidney disease patients undertaking high intensity exercise [abstract no: 067]","volume":"16","author":"Fassett","year":"2011","journal-title":"Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD007784.pub3-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1592\/phco.27.2.183","article-title":"Effect of atorvastatin on cognitive function in patients from the Lipid Lowering and Onset of Renal Disease (LORD) trial","volume":"27","author":"Summers","year":"2007","journal-title":"Pharmacotherapy: The Journal of Human Pharmacology & Drug Therapy"},{"issue":"1","key":"10.1002\/14651858.CD007784.pub3-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1080\/0886022X.2018.1535983","article-title":"Effect of atorvastatin on iron metabolism regulation in patients with chronic kidney disease - a randomized double blind crossover study","volume":"40","author":"Masajtis-Zagajewska","year":"2018","journal-title":"Renal Failure"},{"issue":"10","key":"10.1002\/14651858.CD007784.pub3-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1253\/circj.CJ-08-0095","article-title":"The relationship between the effect of pravastatin and risk factors for coronary heart disease in Japanese patients with hypercholesterolemia","volume":"72","author":"Ishikawa","year":"2008","journal-title":"Circulation Journal"},{"issue":"9","key":"10.1002\/14651858.CD007784.pub3-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1253\/circj.68.860","article-title":"Design and baseline characteristics of a study of primary prevention of coronary events with pravastatin among Japanese with mildly elevated cholesterol levels","volume":"68","author":"Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study Group","year":"2004","journal-title":"Circulation Journal"},{"issue":"4","key":"10.1002\/14651858.CD007784.pub3-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1161\/CIRCULATIONAHA.106.671826","article-title":"Usefulness of pravastatin in primary prevention of cardiovascular events in women: analysis of the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA study)","volume":"117","author":"Mizuno","year":"2008","journal-title":"Circulation"},{"issue":"9542","key":"10.1002\/14651858.CD007784.pub3-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0140-6736(06)69472-5","article-title":"Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial","volume":"368","author":"Nakamura","year":"2006","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD007784.pub3-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.atherosclerosis.2009.03.031","article-title":"Pravastatin and cardiovascular risk in moderate chronic kidney disease","volume":"206","author":"Nakamura","year":"2009","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1002\/14651858.CD007784.pub3-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.atherosclerosissup.2007.02.003","article-title":"Primary prevention of cardiovascular diseases among hypercholesterolemic Japanese with a low dose of pravastatin","volume":"8","author":"Nakamura","year":"2007","journal-title":"Atherosclerosis Supplements"},{"issue":"10","key":"10.1002\/14651858.CD007784.pub3-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1002\/sim.3065","article-title":"Estimation of treatment effect adjusting for treatment changes using the intensity score method: application to a large primary prevention study for coronary events (MEGA study)","volume":"27","author":"Tanaka","year":"2008","journal-title":"Statistics in Medicine"},{"issue":"10","key":"10.1002\/14651858.CD007784.pub3-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1253\/circj.CJ-08-0191","article-title":"Practical risk prediction tools for coronary heart disease in mild to moderate hypercholesterolemia in Japan: originated from the MEGA study data","volume":"72","author":"Teramoto","year":"2008","journal-title":"Circulation Journal"},{"issue":"1-2","key":"10.1002\/14651858.CD007784.pub3-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jns.2009.04.002","article-title":"Risk factors for stroke and lipid-lowering effect of pravastatin on the risk of stroke in Japanese patients with hypercholesterolemia: analysis of data from the MEGA Study, a large randomized controlled trial","volume":"284","author":"Uchiyama","year":"2009","journal-title":"Journal of the Neurological Sciences"},{"issue":"4","key":"10.1002\/14651858.CD007784.pub3-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1177\/1740774507081224","article-title":"Estimation of treatment effect adjusting for dependent censoring using the IPCW method: an application to a large primary prevention study for coronary events (MEGA study)","volume":"4","author":"Yoshida","year":"2007","journal-title":"Clinical Trials"},{"issue":"3","key":"10.1002\/14651858.CD007784.pub3-BIB0150|cit150","first-page":"265","article-title":"Effect of pravastatin on microalbuminuria in patients with non-insulin-dependent diabetes mellitus","volume":"35","author":"Mori","year":"1992","journal-title":"Journal of the Japan Diabetes Society"},{"issue":"4","key":"10.1002\/14651858.CD007784.pub3-BIB0151|cit151","first-page":"341","article-title":"Effect of pravastatin on microalbuminuria in patients with non-insulin-dependent diabetes mellitus - a randomized control study","volume":"39","author":"Mori","year":"1992","journal-title":"Jikeikai Medical Journal"},{"issue":"5","key":"10.1002\/14651858.CD007784.pub3-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1093\/ndt\/17.5.798","article-title":"Effect of cerivastatin on proteinuria and urinary podocytes in patients with chronic glomerulonephritis","volume":"17","author":"Nakamura","year":"2002","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"11","key":"10.1002\/14651858.CD007784.pub3-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.2337\/diacare.28.11.2728","article-title":"Effect of pitavastatin on urinary liver-type fatty acid-binding protein levels in patients with early diabetic nephropathy","volume":"28","author":"Nakamura","year":"2005","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1002\/14651858.CD007784.pub3-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1159\/000091956","article-title":"Effect of pitavastatin on urinary liver-type fatty-acid-binding protein in patients with nondiabetic mild chronic kidney disease","volume":"26","author":"Nakamura","year":"2006","journal-title":"American Journal of Nephrology"},{"issue":"12","key":"10.1002\/14651858.CD007784.pub3-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.2337\/dc07-0919","article-title":"Simvastatin reduces plasma osteoprotegerin in type 2 diabetic patients with microalbuminuria","volume":"30","author":"Nellemann","year":"2007","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1002\/14651858.CD007784.pub3-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/BF02374502","article-title":"Renal function and insulin sensitivity during simvastatin treatment in type 2 (non-insulin-dependent) diabetic patients with microalbuminuria","volume":"36","author":"Nielsen","year":"1993","journal-title":"Diabetologia"},{"key":"10.1002\/14651858.CD007784.pub3-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/s12944-015-0164-5","article-title":"Effects of pitavastatin add-on therapy on chronic kidney disease with albuminuria and dyslipidemia","volume":"14","author":"Ohsawa","year":"2015","journal-title":"Lipids in Health & Disease"},{"issue":"4","key":"10.1002\/14651858.CD007784.pub3-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1530\/EJE-12-0844","article-title":"Atorvastatin administration is associated with dose-related changes in IGF bioavailability","volume":"168","author":"Narayanan","year":"2013","journal-title":"European Journal of Endocrinology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD007784.pub3-BIB0159|cit159","first-page":"S466","article-title":"Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA): trial results [abstract no: 1207]","volume":"52","author":"Rutter","year":"2009","journal-title":"Diabetologia"},{"issue":"1","key":"10.1002\/14651858.CD007784.pub3-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/j.1464-5491.2010.03139.x","article-title":"Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA): a randomized double-blind placebo-controlled trial of high- vs. low-dose atorvastatin","volume":"28","author":"Rutter","year":"2011","journal-title":"Diabetic Medicine"},{"issue":"1","key":"10.1002\/14651858.CD007784.pub3-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jacl.2017.10.011","article-title":"A comparison of the effects of low- and high-dose atorvastatin on lipoprotein metabolism and inflammatory cytokines in type 2 diabetes: results from the Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA) randomized trial","volume":"12","author":"Soran","year":"2018","journal-title":"Journal of Clinical Lipidology"},{"issue":"1","key":"10.1002\/14651858.CD007784.pub3-BIB0162|cit162","first-page":"38","article-title":"Effect of simvastatin on plasma asymmetric dimethylarginine concentration in patients with chronic kidney disease","volume":"21","author":"Panichi","year":"2008","journal-title":"Journal of Nephrology"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD007784.pub3-BIB0163|cit163","first-page":"v75","article-title":"Effect of simvastatin therapy on inflammatory markers and lipids in pre-dialysis patients [abstract no: SP167]","volume":"20","author":"Panichi","year":"2005","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"2","key":"10.1002\/14651858.CD007784.pub3-BIB0164|cit164","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1093\/ndt\/gfi224","article-title":"In vivo and in vitro effects of simvastatin on inflammatory markers in pre-dialysis patients","volume":"21","author":"Panichi","year":"2006","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"10","key":"10.1002\/14651858.CD007784.pub3-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1093\/ndt\/gfy159","article-title":"Proteinuria and cholesterol reduction are independently associated with less renal function decline in statin-treated patients; a post hoc analysis of the PLANET trials","volume":"34","author":"Idzerda","year":"2019","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD007784.pub3-BIB0166|cit166","first-page":"500","article-title":"Association between individual cholesterol and albuminuria response and exposure to atorvastatin or rosuvastatin [abstract no: FR-PO253]","volume":"30","author":"Kroonen","year":"2019","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD007784.pub3-BIB0167|cit167","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S2213-8587(14)70246-3","article-title":"Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial","volume":"3","author":"Zeeuw","year":"2015","journal-title":"The Lancet Diabetes & Endocrinology"},{"issue":"10","key":"10.1002\/14651858.CD007784.pub3-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1093\/ndt\/gfy159","article-title":"Proteinuria and cholesterol reduction are independently associated with less renal function decline in statin-treated patients; a post hoc analysis of the PLANET trials","volume":"34","author":"Idzerda","year":"2019","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD007784.pub3-BIB0169|cit169","first-page":"500","article-title":"Association between individual cholesterol and albuminuria response and exposure to atorvastatin or rosuvastatin [abstract no: FR-PO253]","volume":"30","author":"Kroonen","year":"2019","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD007784.pub3-BIB0170|cit170","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S2213-8587(14)70246-3","article-title":"Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial","volume":"3","author":"Zeeuw","year":"2015","journal-title":"The Lancet Diabetes & Endocrinology"},{"issue":"8","key":"10.1002\/14651858.CD007784.pub3-BIB0171|cit171","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/0895-4356(92)90068-X","article-title":"A coronary primary prevention study of Scottish men aged 45-64 years: trial design. The West of Scotland Coronary Prevention Study Group","volume":"45","year":"1992","journal-title":"Journal of Clinical Epidemiology"},{"issue":"6","key":"10.1002\/14651858.CD007784.pub3-BIB0172|cit172","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/S0002-9149(96)00863-6","article-title":"Baseline risk factors and their association with outcome in the West of Scotland Coronary Prevention Study. The West of Scotland Coronary Prevention Study Group","volume":"79","year":"1997","journal-title":"American Journal of Cardiology"},{"issue":"10","key":"10.1002\/14651858.CD007784.pub3-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1136\/jech.2009.088427","article-title":"Socioeconomic status and telomere length: the West of Scotland Coronary Prevention Study","volume":"63","author":"Batty","year":"2009","journal-title":"Journal of Epidemiology & Community Health"},{"issue":"9556","key":"10.1002\/14651858.CD007784.pub3-BIB0174|cit174","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0140-6736(07)60071-3","article-title":"Telomere length, risk of coronary heart disease, and statin treatment in the West of Scotland Primary Prevention Study: a nested case-control study","volume":"369","author":"Brouilette","year":"2007","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD007784.pub3-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1161\/01.CIR.103.3.387","article-title":"Reduction of stroke events with pravastatin: the Prospective Pravastatin Pooling (PPP) Project","volume":"103","author":"Byington","year":"2001","journal-title":"Circulation"},{"issue":"7122","key":"10.1002\/14651858.CD007784.pub3-BIB0176|cit176","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1136\/bmj.315.7122.1577","article-title":"The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin","volume":"315","author":"Caro","year":"1997","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD007784.pub3-BIB0177|cit177","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1053\/euhj.1999.1193","article-title":"International economic analysis of primary prevention of cardiovascular disease with pravastatin in WOSCOPS. West of Scotland Coronary Prevention Study","volume":"20","author":"Caro","year":"1999","journal-title":"European Heart Journal"},{"issue":"12","key":"10.1002\/14651858.CD007784.pub3-BIB0178|cit178","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1016\/0895-4356(95)00530-7","article-title":"Computerised record linkage: compared with traditional patient follow-up methods in clinical trials and illustrated in a prospective epidemiological study. The West of Scotland Coronary Prevention Study Group","volume":"48","year":"1995","journal-title":"Journal of Clinical Epidemiology"},{"issue":"6","key":"10.1002\/14651858.CD007784.pub3-BIB0179|cit179","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1177\/1740774508098464","article-title":"Parametric conditional frailty models for recurrent cardiovascular events in the lipid study","volume":"5","author":"Cui","year":"2008","journal-title":"Clinical Trials"},{"issue":"2","key":"10.1002\/14651858.CD007784.pub3-BIB0180|cit180","first-page":"194","article-title":"Long-term follow-up of the West of Scotland Coronary Prevention Study","volume":"358","author":"DeFilippis","year":"2008","journal-title":"New England Journal of Medicine"},{"issue":"12","key":"10.1002\/14651858.CD007784.pub3-BIB0181|cit181","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/S0002-9149(99)80259-8","article-title":"Design, rational, and baseline characteristics of the Prospective Pravastatin Pooling (PPP) project--a combined analysis of three large-scale randomized trials: Long-term Intervention with Pravastatin in Ischemic Disease (LIPID), Cholesterol and Recurrent Events (CARE), and West of Scotland Coronary Prevention Study (WOSCOPS)","volume":"76","year":"1995","journal-title":"American Journal of Cardiology"},{"issue":"15","key":"10.1002\/14651858.CD007784.pub3-BIB0182|cit182","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMoa065994","article-title":"Long-term follow-up of the West of Scotland Coronary Prevention Study","volume":"357","author":"Ford","year":"2007","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD007784.pub3-BIB0183|cit183","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.2337\/diabetes.51.5.1596","article-title":"C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study","volume":"51","author":"Freeman","year":"2002","journal-title":"Diabetes"},{"issue":"9","key":"10.1002\/14651858.CD007784.pub3-BIB0184|cit184","doi-asserted-by":"crossref","first-page":"656","DOI":"10.7326\/0003-4819-148-9-200805060-00005","article-title":"Monitoring cholesterol levels: measurement error or true change?","volume":"148","author":"Glasziou","year":"2008","journal-title":"Annals of Internal Medicine"},{"issue":"23","key":"10.1002\/14651858.CD007784.pub3-BIB0185|cit185","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1161\/01.CIR.98.23.2513","article-title":"Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators","volume":"98","author":"Goldberg","year":"1998","journal-title":"Circulation"},{"issue":"4","key":"10.1002\/14651858.CD007784.pub3-BIB0186|cit186","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1067\/mhj.2003.1","article-title":"Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study","volume":"145","author":"Hague","year":"2003","journal-title":"American Heart Journal"},{"issue":"15","key":"10.1002\/14651858.CD007784.pub3-BIB0187|cit187","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1161\/01.CIR.97.15.1440","article-title":"Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS)","volume":"97","year":"1998","journal-title":"Circulation"},{"issue":"9315","key":"10.1002\/14651858.CD007784.pub3-BIB0188|cit188","first-page":"1379","article-title":"Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up.[Erratum appears in Lancet 2002 Nov 2;360(9343):1430]","volume":"359","author":"LIPID Study Group","year":"2002","journal-title":"Lancet"},{"issue":"9","key":"10.1002\/14651858.CD007784.pub3-BIB0189|cit189","doi-asserted-by":"crossref","first-page":"681","DOI":"10.7326\/0003-4819-129-9-199811010-00002","article-title":"Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial","volume":"129","author":"Lewis","year":"1998","journal-title":"Annals of Internal Medicine"},{"issue":"12","key":"10.1002\/14651858.CD007784.pub3-BIB0190|cit190","first-page":"65","article-title":"Long-term follow-up of the West of Scotland Coronary Prevention Study","volume":"47","author":"Liakishev","year":"2007","journal-title":"Kardiologiia"},{"issue":"4","key":"10.1002\/14651858.CD007784.pub3-BIB0191|cit191","first-page":"553","article-title":"Blood rheology, cardiovascular risk factors, and cardiovascular disease: the West of Scotland Coronary Prevention Study.[Erratum appears in Thromb Haemost 2001 May;85(5):946]","volume":"84","author":"Lowe","year":"2000","journal-title":"Thrombosis & Haemostasis"},{"issue":"1","key":"10.1002\/14651858.CD007784.pub3-BIB0192|cit192","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jelectrocard.2006.05.003","article-title":"The value of the electrocardiogram in risk assessment in primary prevention: experience from the West of Scotland Coronary Prevention Study","volume":"40","author":"Macfarlane","year":"2007","journal-title":"Journal of Electrocardiology"},{"issue":"2","key":"10.1002\/14651858.CD007784.pub3-BIB0193|cit193","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1056\/NEJMc076463","article-title":"Long-term follow-up of the West of Scotland Coronary Prevention Study","volume":"358","author":"McEvoy","year":"2008","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD007784.pub3-BIB0194|cit194","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1093\/ajcn\/81.6.1322","article-title":"Relation of diet to cardiovascular disease risk factors in subjects with cardiovascular disease in Australia and New Zealand: analysis of the Long-Term Intervention with Pravastatin in Ischaemic Disease trial","volume":"81","author":"Nestel","year":"2005","journal-title":"American Journal of Clinical Nutrition"},{"issue":"16","key":"10.1002\/14651858.CD007784.pub3-BIB0195|cit195","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1056\/NEJM200010193431603","article-title":"Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group","volume":"343","author":"Packard","year":"2000","journal-title":"New England Journal of Medicine"},{"issue":"20","key":"10.1002\/14651858.CD007784.pub3-BIB0196|cit196","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1161\/01.CIR.0000017634.00171.24","article-title":"Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project","volume":"105","author":"Pfeffer","year":"2002","journal-title":"Circulation"},{"issue":"19","key":"10.1002\/14651858.CD007784.pub3-BIB0197|cit197","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199811053391902","article-title":"Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels","volume":"339","year":"1998","journal-title":"New England Journal of Medicine"},{"issue":"9255","key":"10.1002\/14651858.CD007784.pub3-BIB0198|cit198","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/S0140-6736(00)04042-3","article-title":"Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomised controlled trial. Long-term Intervention with Pravastatin in Ischaemic Disease","volume":"357","author":"Reid","year":"2001","journal-title":"Lancet"},{"issue":"14","key":"10.1002\/14651858.CD007784.pub3-BIB0199|cit199","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","article-title":"The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators","volume":"335","author":"Sacks","year":"1996","journal-title":"New England Journal of Medicine"},{"issue":"15","key":"10.1002\/14651858.CD007784.pub3-BIB0200|cit200","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1016\/0002-9149(91)90276-Q","article-title":"Rationale and design of a secondary prevention trial of lowering normal plasma cholesterol levels after acute myocardial infarction: the Cholesterol and Recurrent Events trial (CARE).[erratum appears in Am J Cardiol 1992 Feb 15;69(5):574]","volume":"68","author":"Sacks","year":"1991","journal-title":"American Journal of Cardiology"},{"issue":"16","key":"10.1002\/14651858.CD007784.pub3-BIB0201|cit201","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1161\/01.CIR.102.16.1893","article-title":"Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project","volume":"102","author":"Sacks","year":"2000","journal-title":"Circulation"},{"issue":"4","key":"10.1002\/14651858.CD007784.pub3-BIB0202|cit202","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1161\/01.CIR.0000080897.52664.94","article-title":"Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study","volume":"108","author":"Sattar","year":"2003","journal-title":"Circulation"},{"issue":"11","key":"10.1002\/14651858.CD007784.pub3-BIB0203|cit203","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.2337\/diabetes.53.11.2855","article-title":"Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the west of Scotland coronary prevention study","volume":"53","author":"Sattar","year":"2004","journal-title":"Diabetes"},{"issue":"7","key":"10.1002\/14651858.CD007784.pub3-BIB0204|cit204","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S0002-9149(99)80135-0","article-title":"Screening experience and baseline characteristics in the West of Scotland Coronary Prevention Study. The WOSCOPS Study Group. West of Scotland Coronary Prevention Study","volume":"76","year":"1995","journal-title":"American Journal of Cardiology"},{"issue":"20","key":"10.1002\/14651858.CD007784.pub3-BIB0205|cit205","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","article-title":"Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group","volume":"333","author":"Shepherd","year":"1995","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD007784.pub3-BIB0206|cit206","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1159\/000066408","article-title":"The anatomy of a clinical trial. The West of Scotland Coronary Prevention Study","volume":"11 Suppl 2","author":"Shepherd","year":"2002","journal-title":"Medical Principles & Practice"},{"issue":"9","key":"10.1002\/14651858.CD007784.pub3-BIB0207|cit207","doi-asserted-by":"crossref","first-page":"113C","DOI":"10.1016\/S0002-9149(99)80480-9","article-title":"The West of Scotland Coronary Prevention Study: a trial of cholesterol reduction in Scottish men","volume":"76","author":"Shepherd","year":"1995","journal-title":"American Journal of Cardiology"},{"issue":"3","key":"10.1002\/14651858.CD007784.pub3-BIB0208|cit208","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1053\/euhj.2001.2775","article-title":"Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels. The Prospective Pravastatin Pooling project","volume":"23","author":"Simes","year":"2002","journal-title":"European Heart Journal"},{"issue":"9","key":"10.1002\/14651858.CD007784.pub3-BIB0209|cit209","doi-asserted-by":"crossref","first-page":"122C","DOI":"10.1016\/S0002-9149(99)80482-2","article-title":"Prospective meta-analysis of cholesterol-lowering studies: the Prospective Pravastatin Pooling (PPP) Project and the Cholesterol Treatment Trialists (CTT) Collaboration","volume":"76","author":"Simes","year":"1995","journal-title":"American Journal of Cardiology"},{"issue":"1","key":"10.1002\/14651858.CD007784.pub3-BIB0210|cit210","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/ijo.2008.224","article-title":"Leptin, but not adiponectin, is a predictor of recurrent cardiovascular events in men: results from the LIPID study","volume":"33","author":"Soderberg","year":"2009","journal-title":"International Journal of Obesity"},{"issue":"1269","key":"10.1002\/14651858.CD007784.pub3-BIB0211|cit211","first-page":"11","article-title":"Differences in cardiovascular mortality between Australia and New Zealand according to socioeconomic status: findings from the Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study","volume":"121","author":"Stewart","year":"2008","journal-title":"New Zealand Medical Journal"},{"issue":"22","key":"10.1002\/14651858.CD007784.pub3-BIB0212|cit212","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1016\/j.ehj.2003.08.017","article-title":"Depression and cardiovascular morbidity and mortality: cause or consequence?","volume":"24","author":"Stewart","year":"2003","journal-title":"European Heart Journal"},{"issue":"20","key":"10.1002\/14651858.CD007784.pub3-BIB0213|cit213","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1001\/archinte.160.20.3144","article-title":"Long-term assessment of psychological well-being in a randomized placebo-controlled trial of cholesterol reduction with pravastatin. The LIPID Study Investigators","volume":"160","author":"Stewart","year":"2000","journal-title":"Archives of Internal Medicine"},{"issue":"7","key":"10.1002\/14651858.CD007784.pub3-BIB0214|cit214","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S0002-9149(02)02599-7","article-title":"Factors affecting low-density lipoprotein and high-density lipoprotein cholesterol response to pravastatin in the West Of Scotland Coronary Prevention Study (WOSCOPS)","volume":"90","author":"Streja","year":"2002","journal-title":"American Journal of Cardiology"},{"issue":"4","key":"10.1002\/14651858.CD007784.pub3-BIB0215|cit215","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/S0735-1097(98)00657-3","article-title":"The effects of pravastatin on hospital admission in hypercholesterolemic middle-aged men: West of Scotland Coronary Prevention Study","volume":"33","year":"1999","journal-title":"Journal of the American College of Cardiology"},{"issue":"2","key":"10.1002\/14651858.CD007784.pub3-BIB0216|cit216","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1161\/CIRCULATIONAHA.104.517565","article-title":"Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease","volume":"112","author":"Tonelli","year":"2005","journal-title":"Circulation"},{"issue":"12","key":"10.1002\/14651858.CD007784.pub3-BIB0217|cit217","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1161\/01.CIR.0000143892.84582.60","article-title":"Effect of pravastatin on cardiovascular events in people with chronic kidney disease","volume":"110","author":"Tonelli","year":"2004","journal-title":"Circulation"},{"issue":"7555","key":"10.1002\/14651858.CD007784.pub3-BIB0218|cit218","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1136\/bmj.38814.566019.2F","article-title":"Proteinuria, impaired kidney function, and adverse outcomes in people with coronary disease: analysis of a previously conducted randomised trial","volume":"332","author":"Tonelli","year":"2006","journal-title":"BMJ"},{"issue":"12","key":"10.1002\/14651858.CD007784.pub3-BIB0219|cit219","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.1681\/ASN.2005070779","article-title":"Effect of pravastatin in people with diabetes and chronic kidney disease","volume":"16","author":"Tonelli","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"issue":"September, Prog","key":"10.1002\/14651858.CD007784.pub3-BIB0220|cit220","first-page":"257A","article-title":"Effect of pravastatin on loss of renal function in patients with CKD [abstract no: F-P0996]","volume":"13","author":"Tonelli","year":"2002","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD007784.pub3-BIB0221|cit221","first-page":"252A","article-title":"Pravastatin is effective for secondary prevention of cardiovascular events in patients with chronic renal insufficiency (CRI) [abstract]","volume":"12","author":"Tonelli","year":"2001","journal-title":"Journal of the American Society of Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD007784.pub3-BIB0222|cit222","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1097\/01.ASN.0000068461.45784.2F","article-title":"Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease","volume":"14","author":"Tonelli","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD007784.pub3-BIB0223|cit223","doi-asserted-by":"crossref","first-page":"98","DOI":"10.7326\/0003-4819-138-2-200301210-00010","article-title":"Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency","volume":"138","author":"Tonelli","year":"2003","journal-title":"Annals of Internal Medicine"},{"issue":"1","key":"10.1002\/14651858.CD007784.pub3-BIB0224|cit224","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1523-1755.2005.00398.x","article-title":"Biomarkers of inflammation and progression of chronic kidney disease","volume":"68","author":"Tonelli","year":"2005","journal-title":"Kidney International"},{"issue":"8","key":"10.1002\/14651858.CD007784.pub3-BIB0225|cit225","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/sj.jhh.1002036","article-title":"Effect of pravastatin on blood pressure in people with cardiovascular disease","volume":"20","author":"Tonelli","year":"2006","journal-title":"Journal of Human Hypertension"},{"issue":"2","key":"10.1002\/14651858.CD007784.pub3-BIB0226|cit226","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1056\/NEJMc076463","article-title":"Long-term follow-up of the West of Scotland Coronary Prevention Study","volume":"358","author":"Tsubokura","year":"2008","journal-title":"New England Journal of Medicine"},{"issue":"25","key":"10.1002\/14651858.CD007784.pub3-BIB0227|cit227","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1161\/hc5001.101061","article-title":"Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS)","volume":"104","author":"Wallace","year":"2001","journal-title":"Circulation"},{"issue":"7","key":"10.1002\/14651858.CD007784.pub3-BIB0228|cit228","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/eurheartj\/ehn007","article-title":"The value of N-terminal fragment of brain natriuretic peptide and tissue inhibitor of metalloproteinase-1 levels as predictors of cardiovascular outcome in the LIPID study","volume":"29","author":"West","year":"2008","journal-title":"European Heart Journal"},{"issue":"12","key":"10.1002\/14651858.CD007784.pub3-BIB0229|cit229","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1097\/00004872-200212000-00032","article-title":"Risk factors for non-haemorrhagic stroke in patients with coronary heart disease and the effect of lipid-modifying therapy with pravastatin","volume":"20","author":"West","year":"2002","journal-title":"Journal of Hypertension"},{"issue":"9038","key":"10.1002\/14651858.CD007784.pub3-BIB0230|cit230","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/S0140-6736(96)04292-4","article-title":"West of Scotland Coronary Prevention Study: identification of high-risk groups and comparison with other cardiovascular intervention trials","volume":"348","year":"1996","journal-title":"Lancet"},{"issue":"5","key":"10.1002\/14651858.CD007784.pub3-BIB0231|cit231","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJM200008033430502","article-title":"Pravastatin therapy and the risk of stroke","volume":"343","author":"White","year":"2000","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD007784.pub3-BIB0232|cit232","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0021-9150(02)00196-X","article-title":"Association of the factor XII 46C>T polymorphism with risk of coronary heart disease (CHD) in the WOSCOPS study","volume":"165","author":"Zito","year":"2002","journal-title":"Atherosclerosis"},{"issue":"18","key":"10.1002\/14651858.CD007784.pub3-BIB0233|cit233","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1161\/01.CIR.0000146378.65439.7A","article-title":"Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria","volume":"110","author":"Asselbergs","year":"2004","journal-title":"Circulation"},{"issue":"3","key":"10.1002\/14651858.CD007784.pub3-BIB0234|cit234","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1161\/01.STR.0000155731.92786.e9","article-title":"Effects of fosinopril and pravastatin on carotid intima-media thickness in subjects with increased albuminuria","volume":"36","author":"Asselbergs","year":"2005","journal-title":"Stroke"},{"issue":"1","key":"10.1002\/14651858.CD007784.pub3-BIB0235|cit235","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.atherosclerosis.2006.11.011","article-title":"Long-term effects of pravastatin and fosinopril on peripheral endothelial function in albuminuric subjects","volume":"196","author":"Asselbergs","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1002\/14651858.CD007784.pub3-BIB0236|cit236","first-page":"36A","article-title":"Cost-effectiveness of screening for albuminuria and subsequent treatment with an ACE-inhibitor; a pharmaco-economic analysis [abstract no: TH-FC169]","volume":"16","author":"Atthobari","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD007784.pub3-BIB0237|cit237","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.clinthera.2006.03.012","article-title":"Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: A pharmacoeconomic analysis linked to the prevention of renal and vascular endstage disease (PREVEND) study and the prevention of renal and vascular endstage disease intervention trial (PREVEND IT)","volume":"28","author":"Atthobari","year":"2006","journal-title":"Clinical Therapeutics"},{"key":"10.1002\/14651858.CD007784.pub3-BIB0238|cit238","first-page":"71A","article-title":"The effect of statins on urinary albumin excretion (UAE) and glomerular filtration rate (GFR): a randomized controlled trial (RCT) and observational cohort study [abstract no: F-FC151]","volume":"16","author":"Atthobari","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"issue":"11","key":"10.1002\/14651858.CD007784.pub3-BIB0239|cit239","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.1093\/ndt\/gfl244","article-title":"The effect of statins on urinary albumin excretion and glomerular filtration rate: results from both a randomized clinical trial and an observational cohort study","volume":"21","author":"Atthobari","year":"2006","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"6","key":"10.1002\/14651858.CD007784.pub3-BIB0240|cit240","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1093\/ndt\/gfm091","article-title":"Impact of weight change on albuminuria in the general population","volume":"22","author":"Bello","year":"2007","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"6","key":"10.1002\/14651858.CD007784.pub3-BIB0241|cit241","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.ahj.2011.03.028","article-title":"Long-term effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria: ten years of follow-up of Prevention of Renal and Vascular End-stage Disease Intervention Trial (PREVEND IT)","volume":"161","author":"Brouwers","year":"2011","journal-title":"American Heart Journal"},{"issue":"1","key":"10.1002\/14651858.CD007784.pub3-BIB0242|cit242","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1093\/ndt\/gfz266","article-title":"Fibroblast growth factor 23 and new-onset chronic kidney disease in the general population: the Prevention of Renal and Vascular Endstage Disease (PREVEND) study","volume":"36","author":"De Jong","year":"2021","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"6","key":"10.1002\/14651858.CD007784.pub3-BIB0243|cit243","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0002-9149(00)01042-0","article-title":"Rationale, design, and baseline characteristics of a trial of prevention of cardiovascular and renal disease with fosinopril and pravastatin in nonhypertensive, nonhypercholesterolemic subjects with microalbuminuria (the Prevention of REnal and Vascular ENdstage Disease Intervention Trial [PREVEND IT])","volume":"86","author":"Diercks","year":"2000","journal-title":"American Journal of Cardiology"},{"issue":"13","key":"10.1002\/14651858.CD007784.pub3-BIB0244|cit244","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1093\/eurheartj\/ehi253","article-title":"Impact of statins in microalbuminuric subjects with the metabolic syndrome: a substudy of the PREVEND Intervention Trial","volume":"26","author":"Geluk","year":"2005","journal-title":"European Heart Journal"},{"issue":"3","key":"10.1002\/14651858.CD007784.pub3-BIB0245|cit245","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1093\/jac\/dks419","article-title":"Effect of pravastatin and fosinopril on recurrent urinary tract infections","volume":"68","author":"Pouwels","year":"2013","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"5","key":"10.1002\/14651858.CD007784.pub3-BIB0246|cit246","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1161\/01.HYP.0000244082.26293.2d","article-title":"Predictors of angiotensin-converting enzyme inhibitor-induced reduction of urinary albumin excretion in nondiabetic patients","volume":"48","author":"de Wal","year":"2006","journal-title":"Hypertension"},{"issue":"4","key":"10.1002\/14651858.CD007784.pub3-BIB0247|cit247","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3317\/jraas.2007.029","article-title":"Plasma matrix metalloproteinase-9 and ACE-inhibitor-induced improvement of urinary albumin excretion in non-diabetic, microalbuminuric subjects","volume":"8","author":"de Wal","year":"2007","journal-title":"Journal of the Renin-Angiotensin-Aldosterone System"},{"issue":"2","key":"10.1002\/14651858.CD007784.pub3-BIB0248|cit248","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.amjcard.2008.02.108","article-title":"Effect of fosinopril treatment on serum C-reactive protein levels in patients with microalbuminuria","volume":"102","author":"Harst","year":"2008","journal-title":"American Journal of Cardiology"},{"key":"10.1002\/14651858.CD007784.pub3-BIB0249|cit249","first-page":"1183","article-title":"A clinical trial comparing the treatment of hypercholesterolaemia with simvastatin and diet versus diet alone in patients with idiopathic membranous nephropathy: a preliminary report [abstract]","volume":"43","author":"Rayner","year":"1993","journal-title":"Kidney International"},{"key":"10.1002\/14651858.CD007784.pub3-BIB0250|cit250","unstructured":"Rayner BL Byrne M van Zyl-Smit R A clinical trial comparing the treatment of hypercholesterolaemia with simvastatin (sv) and diet versus diet alone in patients with idiopathic membranous nephropathy (IMN) [abstract] 12th International Congress of Nephrology; 1993 Jun 13-18; Jerusalem, Israel 1993 76"},{"issue":"7","key":"10.1002\/14651858.CD007784.pub3-BIB0251|cit251","first-page":"963","article-title":"Treatment of hyperlipidaemia with simvastatin (SV) and diet, vs diet alone in idiopathic membranous nephropathy (IMN) [abstract]","volume":"9","author":"Rayner","year":"1994","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD007784.pub3-BIB0252|cit252","first-page":"219","article-title":"A prospective clinical trial comparing the treatment of idiopathic membranous nephropathy and nephrotic syndrome with simvastatin and diet, versus diet alone","volume":"46","author":"Rayner","year":"1996","journal-title":"Clinical Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD007784.pub3-BIB0253|cit253","doi-asserted-by":"crossref","first-page":"547","DOI":"10.18388\/abp.2010_2442","article-title":"Atorvastatin improves tubular status in non-diabetic patients with chronic kidney disease - placebo controlled, randomized, cross-over study","volume":"57","author":"Renke","year":"2010","journal-title":"Acta Biochimica Polonica"},{"issue":"6","key":"10.1002\/14651858.CD007784.pub3-BIB0254|cit254","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1161\/CIRCULATIONAHA.106.654756","article-title":"Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE)","volume":"115","author":"Deedwania","year":"2007","journal-title":"Circulation"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD007784.pub3-BIB0255|cit255","first-page":"743A","article-title":"Improvement in renal function with intensive statin therapy in older patients without increased muscle symptoms: the SAGE trial [abstract no: SA-PO2762]","volume":"20","author":"Deedwania","year":"2009","journal-title":"Journal of the American Society of Nephrology"},{"issue":"12","key":"10.1002\/14651858.CD007784.pub3-BIB0256|cit256","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1007\/s40266-015-0328-z","article-title":"Improvement in renal function and reduction in serum uric acid with intensive statin therapy in older patients: a post hoc analysis of the SAGE trial","volume":"32","author":"Deedwania","year":"2015","journal-title":"Drugs & Aging"},{"issue":"6","key":"10.1002\/14651858.CD007784.pub3-BIB0257|cit257","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.ahj.2004.06.026","article-title":"Effect of aggressive versus moderate lipid-lowering therapy on myocardial ischemia: the rationale, design, and baseline characteristics of the Study Assessing Goals in the Elderly (SAGE)","volume":"148","author":"Deedwania","year":"2004","journal-title":"American Heart Journal"},{"issue":"10","key":"10.1002\/14651858.CD007784.pub3-BIB0258|cit258","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1038\/sj.ki.5000327","article-title":"Effect of fluvastatin on apolipoprotein-defined lipoprotein subclasses in patients with chronic renal insufficiency","volume":"69","author":"Alaupovic","year":"2006","journal-title":"Kidney International"},{"issue":"1","key":"10.1002\/14651858.CD007784.pub3-BIB0259|cit259","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1053\/ajkd.2002.29883","article-title":"Fluvastatin improves lipid abnormalities in patients with moderate to advanced chronic renal insufficiency","volume":"39","author":"Samuelsson","year":"2002","journal-title":"American Journal of Kidney Diseases"},{"issue":"17","key":"10.1002\/14651858.CD007784.pub3-BIB0260|cit260","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.2169\/internalmedicine.47.1159","article-title":"Effects of lipid-lowering therapy with rosuvastatin on atherosclerotic burden in patients with chronic kidney disease","volume":"47","author":"Sawara","year":"2008","journal-title":"Internal Medicine"},{"key":"10.1002\/14651858.CD007784.pub3-BIB0261|cit261","unstructured":"Sawara Y Takei T Uchida K Tsuchiya K Nitta K Effects of lipid-lowering therapy with rosuvastatin on atherosclerotic burden in patients with chronic kidney disease [abstract no: SA166] World Congress of Nephrology; 2009 May 22-26; Milan, Italy 2009"},{"issue":"10 Pt 1","key":"10.1002\/14651858.CD007784.pub3-BIB0262|cit262","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1093\/ajh\/4.10.868","article-title":"Associated effect of hepatic hydroxymethylglutaryl coenzyme A reductase + angiotensin converting enzyme inhibitors on the progression of renal failure in hypertensive subjects","volume":"4","author":"Scanferla","year":"1991","journal-title":"American Journal of Hypertension"},{"key":"10.1002\/14651858.CD007784.pub3-BIB0263|cit263","unstructured":"Baigent C Landray M Study of Heart and Renal Protection (SHARP): Does lowering cholesterol prevent major vascular events in patients with chronic kidney disease? Final Protocol (Version 5: 12th July 2005) https:\/\/www.ctsu.ox.ac.uk\/files\/download_protocol_en_v5.pdf"},{"issue":"9784","key":"10.1002\/14651858.CD007784.pub3-BIB0264|cit264","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet"},{"issue":"84","key":"10.1002\/14651858.CD007784.pub3-BIB0265|cit265","doi-asserted-by":"crossref","first-page":"S207","DOI":"10.1046\/j.1523-1755.63.s84.4.x","article-title":"Study of Heart and Renal Protection (SHARP)","volume":"63","author":"Baigent","year":"2003","journal-title":"Kidney International - Supplement"},{"issue":"1","key":"10.1002\/14651858.CD007784.pub3-BIB0266|cit266","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1053\/j.ackd.2015.11.004","article-title":"Considerations in applying the results of randomized controlled clinical trials to the care of older adults with kidney disease in the clinical setting: the SHARP trial","volume":"23","author":"Butler","year":"2016","journal-title":"Advances in Chronic Kidney Disease"},{"issue":"8","key":"10.1002\/14651858.CD007784.pub3-BIB0267|cit267","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1681\/ASN.2013090965","article-title":"Effects of lowering LDL cholesterol on progression of kidney disease","volume":"25","author":"Haynes","year":"2014","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD007784.pub3-BIB0268|cit268","first-page":"170A","article-title":"Relevance of renal diagnosis to prognosis of chronic kidney disease: results from the Study of Heart and Renal Protection (SHARP) [abstract no: TH-PO327]","volume":"23","author":"Haynes","year":"2012","journal-title":"Journal of the American Society of Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD007784.pub3-BIB0269|cit269","doi-asserted-by":"crossref","first-page":"914","DOI":"10.2215\/CJN.10371013","article-title":"The effect of lowering LDL cholesterol on vascular access patency: post hoc analysis of the Study of Heart and Renal Protection","volume":"9","author":"Herrington","year":"2014","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"2","key":"10.1002\/14651858.CD007784.pub3-BIB0270|cit270","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1161\/HYPERTENSIONAHA.116.08386","article-title":"Evidence for reverse causality in the association between blood pressure and cardiovascular risk in patients with chronic kidney disease","volume":"69","author":"Herrington","year":"2017","journal-title":"Hypertension"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD007784.pub3-BIB0271|cit271","first-page":"275A","article-title":"The effect of lowering LDL-cholesterol with simvastatin plus ezetimibe on vascular access patency: results from the Study of Heart and Renal Protection (SHARP) [abstract no: TH-PO762]","volume":"23","author":"Herrington","year":"2012","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD007784.pub3-BIB0272|cit272","first-page":"221","article-title":"The relevance of systolic blood pressure to vascular disease in chronic kidney disease patients with and without vascular disease: observations from the Study of Heart and Renal Protection (SHARP) [abstract no: TH-PO586]","volume":"26","author":"Judge","year":"2015","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD007784.pub3-BIB0273|cit273","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s12882-015-0054-0","article-title":"What is the impact of chronic kidney disease stage and cardiovascular disease on the annual cost of hospital care in moderate-to-severe kidney disease?","volume":"16","author":"Kent","year":"2015","journal-title":"BMC Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD007784.pub3-BIB0274|cit274","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2215\/CJN.07320619","article-title":"Apolipoprotein B, triglyceride-rich lipoproteins, and risk of cardiovascular events in persons with CKD","volume":"15","author":"Lamprea-Montealegre","year":"2020","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD007784.pub3-BIB0275|cit275","first-page":"578A","article-title":"Prognostic utility of estimated albumin excretion rate (eAER) in chronic kidney disease (CKD): results from the Study of Heart and Renal Protection (SHARP) [abstract no: FR-PO903]","volume":"25","author":"Mafham","year":"2014","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD007784.pub3-BIB0276|cit276","first-page":"257","article-title":"Prognostic utility of estimated albumin excretion rate in chronic kidney disease: results from the Study of Heart and Renal Protection","volume":"33","author":"Mafham","year":"2018","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD007784.pub3-BIB0277|cit277","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1053\/j.ajkd.2015.09.020","article-title":"Cost-effectiveness of simvastatin plus ezetimibe for cardiovascular prevention in CKD: results of the Study of Heart and Renal Protection (SHARP)","volume":"67","author":"Mihaylova","year":"2016","journal-title":"American Journal of Kidney Diseases"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD007784.pub3-BIB0278|cit278","first-page":"409A","article-title":"Cost-effectiveness of lowering LDL-cholesterol in chronic kidney disease: results from the Study of Heart and Renal Protection (SHARP) [abstract no: FR-PO177]","volume":"23","author":"Mihaylova","year":"2012","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD007784.pub3-BIB0279|cit279","first-page":"795","article-title":"The impact of chronic kidney disease on household income: does health affect wealth? [abstract no: SA-PO729]","volume":"26","author":"Morton","year":"2015","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD007784.pub3-BIB0280|cit280","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1053\/j.ajkd.2015.07.021","article-title":"Impact of educational attainment on health outcomes in moderate to severe CKD","volume":"67","author":"Morton","year":"2016","journal-title":"American Journal of Kidney Diseases"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD007784.pub3-BIB0281|cit281","doi-asserted-by":"crossref","first-page":"iii178","DOI":"10.1093\/ndt\/gfv175.11","article-title":"Impact of educational attainment on health outcomes in moderate-to-severe chronic kidney disease [abstract no: FP329]","volume":"30","author":"Morton","year":"2015","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD007784.pub3-BIB0282|cit282","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s12882-017-0545-2","article-title":"Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: results from the Study of Heart and Renal Protection","volume":"18","author":"Reith","year":"2017","journal-title":"BMC Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD007784.pub3-BIB0283|cit283","first-page":"488A","article-title":"Effect of lowering LDL-cholesterol with simvastatin plus ezetimibe on non-vascular outcomes in patients with chronic kidney disease (CKD): results from the Study of Heart and Renal Protection (SHARP) [abstract no: FR-PO564]","volume":"26","author":"Reith","year":"2015","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD007784.pub3-BIB0284|cit284","first-page":"686A","article-title":"Effect of lowering LDL-cholesterol with simvastatin plus ezetimibe on infection in patients with chronic kidney disease: results from the Study of Heart and Renal Protection (SHARP) [abstract no: SA-PO220]","volume":"23","author":"Reith","year":"2012","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstracts Issue","key":"10.1002\/14651858.CD007784.pub3-BIB0285|cit285","first-page":"817A","article-title":"SHARP: an international randomized placebo-controlled trial of lipid-lowering in chronic kidney disease. 1-year safety and efficacy experience [abstract no: SU-PO1044]","volume":"18","author":"SHARP Collaborative Group","year":"2007","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD007784.pub3-BIB0286|cit286","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.kint.2019.01.028","article-title":"Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease","volume":"96","author":"Schlackow","year":"2019","journal-title":"Kidney International"},{"issue":"5","key":"10.1002\/14651858.CD007784.pub3-BIB0287|cit287","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.ahj.2010.08.012","article-title":"Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease","volume":"160","author":"Sharp Collaborative Group","year":"2010","journal-title":"American Heart Journal"},{"issue":"3","key":"10.1002\/14651858.CD007784.pub3-BIB0288|cit288","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1053\/j.ajkd.2016.02.052","article-title":"Smoking and adverse outcomes in patients with CKD: the Study of Heart and Renal Protection (SHARP)","volume":"68","author":"Staplin","year":"2016","journal-title":"American Journal of Kidney Diseases"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD007784.pub3-BIB0289|cit289","first-page":"660A","article-title":"The effects of cigarette smoking in patients with chronic kidney disease (CKD): results from the Study of Heart and Renal Protection (SHARP) [abstract no: SA-PO158]","volume":"24","author":"Staplin","year":"2013","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD007784.pub3-BIB0290|cit290","first-page":"29A","article-title":"Relevance of LDL cholesterol and C-reactive protein to cardiovascular risk among patients with chronic kidney disease - results from the Study of Heart and Renal Protection [abstract no: TH-OR116]","volume":"26","author":"Storey","year":"2015","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD007784.pub3-BIB0291|cit291","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.kint.2017.09.011","article-title":"Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation","volume":"93","author":"Storey","year":"2018","journal-title":"Kidney International"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD007784.pub3-BIB0292|cit292","first-page":"80","article-title":"The SHARP-ER study: design of the extended follow-up of the SHARP study cohort [abstract no: 235]","volume":"30","author":"Sukkar","year":"2015","journal-title":"Nephrology"},{"key":"10.1002\/14651858.CD007784.pub3-BIB0293|cit293","doi-asserted-by":"crossref","first-page":"2054358119","DOI":"10.1177\/2054358119879896","article-title":"Protocol for the Study of Heart and Renal Protection-extended review: additional 5-year follow-up of the Australian, New Zealand, and Malaysian SHARP cohort","volume":"6","author":"Sukkar","year":"2019","journal-title":"Canadian Journal of Kidney Health and Disease"},{"issue":"1","key":"10.1002\/14651858.CD007784.pub3-BIB0294|cit294","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/nep.14127","article-title":"Comparing survival in patients with chronic kidney disease across three countries \u2013 results from the study of heart and renal protection-extended review","volume":"28","author":"Talbot","year":"2022","journal-title":"Nephrology"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD007784.pub3-BIB0295|cit295","doi-asserted-by":"crossref","first-page":"S250","DOI":"10.1016\/j.ekir.2020.02.646","article-title":"Comparing survival in patients with chronic kidney disease across three countries - results from the study of Heart and Renal Protection-extended review (SHARP-ER) [abstact no: Sun-119]","volume":"5","author":"Talbot","year":"2020","journal-title":"Kidney International Reports"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD007784.pub3-BIB0296|cit296","first-page":"639","article-title":"Cause of death in patients on renal replacement therapy varies across Australia, New Zealand, and Malaysia-results from the study of heart and renal protection-extended review (SHARP-ER) [abstract no: FR-PO834]","volume":"29","author":"Talbot","year":"2018","journal-title":"Journal of the American Society of Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD007784.pub3-BIB0297|cit297","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1080\/00365590510031255","article-title":"Safety and efficacy of atorvastatin in patients with severe renal dysfunction","volume":"39","author":"Holmberg","year":"2005","journal-title":"Scandinavian Journal of Urology & Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD007784.pub3-BIB0298|cit298","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1080\/00365590500329304","article-title":"Low-dose atorvastatin in severe chronic kidney disease patients: a randomized, controlled endpoint study","volume":"39","author":"Stegmayr","year":"2005","journal-title":"Scandinavian Journal of Urology & Nephrology"},{"key":"10.1002\/14651858.CD007784.pub3-BIB0299|cit299","unstructured":"Stegmayr BG Brannstrom M Bucht S Dimeny E Ekspong A Granroth B Safety and efficacy of atorvastatin in patients with impaired renal function [abstract] 38th Congress. European Renal Association. European Dialysis and Transplantation Association; 2001 Jun 24-27; Vienna, Austria 2001 134"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD007784.pub3-BIB0300|cit300","first-page":"161A","article-title":"Safety and efficacy of atorvastatin in patients with severe renal dysfunction [abstract no: A0828]","volume":"9","author":"Stegmayr","year":"1998","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD007784.pub3-BIB0301|cit301","first-page":"268A","article-title":"Safety and efficacy of atorvastatin in patients with severe renal dysfunction [abstract no: A1356]","volume":"10","author":"Stegmayr","year":"1999","journal-title":"Journal of the American Society of Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD007784.pub3-BIB0302|cit302","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1038\/ki.1993.358","article-title":"Simvastatin therapy for hypercholesterolemic patients with nephrotic syndrome or significant proteinuria","volume":"44","author":"Thomas","year":"1993","journal-title":"Kidney International"},{"issue":"13","key":"10.1002\/14651858.CD007784.pub3-BIB0303|cit303","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJMoa064278","article-title":"HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events","volume":"357","author":"Barter","year":"2007","journal-title":"New England Journal of Medicine"},{"issue":"9539","key":"10.1002\/14651858.CD007784.pub3-BIB0304|cit304","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0140-6736(06)69292-1","article-title":"Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study","volume":"368","author":"Deedwania","year":"2006","journal-title":"Lancet"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD007784.pub3-BIB0305|cit305","first-page":"142A","article-title":"Improvement in estimated glomerular filtration rate with atorvastatin in patients with metabolic syndrome: The treating to new targets (TNT) study [abstract no: TH-PO140]","volume":"20","author":"Deedwania","year":"2009","journal-title":"Journal of the American Society of Nephrology"},{"issue":"12","key":"10.1002\/14651858.CD007784.pub3-BIB0306|cit306","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/j.amjcard.2012.02.019","article-title":"Relation of improvement in estimated glomerular filtration rate with atorvastatin to reductions in hospitalizations for heart failure (from the Treating to New Targets [TNT] study)","volume":"109","author":"Ho","year":"2012","journal-title":"American Journal of Cardiology"},{"issue":"10","key":"10.1002\/14651858.CD007784.pub3-BIB0307|cit307","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/j.amjcard.2008.07.023","article-title":"Comparison of effectiveness of atorvastatin 10 mg versus 80 mg in reducing major cardiovascular events and repeat revascularization in patients with previous percutaneous coronary intervention (post hoc analysis of the Treating to New Targets [TNT] Study)","volume":"102","author":"Johnson","year":"2008","journal-title":"American Journal of Cardiology"},{"issue":"23","key":"10.1002\/14651858.CD007784.pub3-BIB0308|cit308","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1161\/CIRCULATIONAHA.107.713438","article-title":"Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment","volume":"117","author":"Kastelein","year":"2008","journal-title":"Circulation"},{"issue":"5","key":"10.1002\/14651858.CD007784.pub3-BIB0309|cit309","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1161\/CIRCULATIONAHA.106.625574","article-title":"Effect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the Treating to New Targets (TNT) study","volume":"115","author":"Khush","year":"2007","journal-title":"Circulation"},{"issue":"5","key":"10.1002\/14651858.CD007784.pub3-BIB0310|cit310","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/j.1751-7176.2008.07851.x","article-title":"The benefits of intensive lipid lowering in patients with stable coronary heart disease with normal or high systolic blood pressure: an analysis of the Treating to New Targets (TNT) study","volume":"10","author":"Kostis","year":"2008","journal-title":"Journal of Clinical Hypertension"},{"issue":"5","key":"10.1002\/14651858.CD007784.pub3-BIB0311|cit311","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.amjcard.2007.03.102","article-title":"Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study)","volume":"100","author":"LaRosa","year":"2007","journal-title":"American Journal of Cardiology"},{"issue":"14","key":"10.1002\/14651858.CD007784.pub3-BIB0312|cit312","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa050461","article-title":"Intensive lipid lowering with atorvastatin in patients with stable coronary disease","volume":"352","author":"LaRosa","year":"2005","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD007784.pub3-BIB0313|cit313","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.ahj.2008.05.032","article-title":"Long-term economic outcomes associated with intensive versus moderate lipid-lowering therapy in coronary artery disease: results from the Treating to New Targets (TNT) Trial","volume":"156","author":"Mark","year":"2008","journal-title":"American Heart Journal"},{"issue":"2","key":"10.1002\/14651858.CD007784.pub3-BIB0314|cit314","doi-asserted-by":"crossref","first-page":"e007387","DOI":"10.1161\/JAHA.117.007387","article-title":"Relationship of high-density lipoprotein cholesterol with renal function in patients treated with atorvastatin","volume":"7","author":"Ong","year":"2018","journal-title":"Journal of the American Heart Association"},{"issue":"20","key":"10.1002\/14651858.CD007784.pub3-BIB0315|cit315","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.jacc.2007.12.054","article-title":"Intensive lipid-lowering with atorvastatin for secondary prevention in patients after coronary artery bypass surgery","volume":"51","author":"Shah","year":"2008","journal-title":"Journal of the American College of Cardiology"},{"issue":"6","key":"10.1002\/14651858.CD007784.pub3-BIB0316|cit316","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.2337\/dc05-2465","article-title":"Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study","volume":"29","author":"Shepherd","year":"2006","journal-title":"Diabetes Care"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD007784.pub3-BIB0317|cit317","first-page":"370A","article-title":"Improved in estimated glomerular filtration rate with atorvastatin predicts reduced cardiovascular risk: the treating to new targets (TNT) study [abstract no: F-PO1118]","volume":"20","author":"Shepherd","year":"2009","journal-title":"Journal of the American Society of Nephrology"},{"issue":"8","key":"10.1002\/14651858.CD007784.pub3-BIB0318|cit318","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.amjcard.2016.01.014","article-title":"Relation between change in renal function and cardiovascular outcomes in atorvastatin-treated patients (from the Treating to New Targets [TNT] Study)","volume":"117","author":"Shepherd","year":"2016","journal-title":"American Journal of Cardiology"},{"issue":"6","key":"10.1002\/14651858.CD007784.pub3-BIB0319|cit319","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.2215\/CJN.04371206","article-title":"Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study","volume":"2","author":"Shepherd","year":"2007","journal-title":"Clinical Journal of The American Society of Nephrology: CJASN"},{"issue":"15","key":"10.1002\/14651858.CD007784.pub3-BIB0320|cit320","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/j.jacc.2007.11.072","article-title":"Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study","volume":"51","author":"Shepherd","year":"2008","journal-title":"Journal of the American College of Cardiology"},{"issue":"8","key":"10.1002\/14651858.CD007784.pub3-BIB0321|cit321","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/S0025-6196(11)60763-5","article-title":"Intensive lipid lowering with atorvastatin in patients with coronary artery disease, diabetes, and chronic kidney disease","volume":"83","author":"Shepherd","year":"2008","journal-title":"Mayo Clinic Proceedings"},{"key":"10.1002\/14651858.CD007784.pub3-BIB0322|cit322","unstructured":"Shepherd J Wenger NK Wilson DJ Intensive lipid lowering with atorvastatin is associated with a significant improvement in renal function: The Treating to New Targets (TNT) study [abstract no: S-FC-019] 4th World Congress of Nephrology. 19th International Congress of the International Society of Nephrology (ISN); 2007 Apr 21-25; Rio de Janeiro, Brazil 2007 44"},{"issue":"Abstracts","key":"10.1002\/14651858.CD007784.pub3-BIB0323|cit323","first-page":"809A","article-title":"Intensive lipid lowering with atorvastatin is associated with significant cardiovascular benefits in patients with and without chronic kidney disease: the Treating to New Targets (TNT) study [abstract no: SA-PO1121]","volume":"17","author":"Shepherd","year":"2006","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstracts Issue","key":"10.1002\/14651858.CD007784.pub3-BIB0324|cit324","first-page":"552A","article-title":"Serum uric acid as a predictor of cardiovascular risk: the treating to new targets (TNT) study [abstract no: F-PO1955]","volume":"19","author":"Shepherd","year":"2008","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstracts Issue","key":"10.1002\/14651858.CD007784.pub3-BIB0325|cit325","first-page":"306A","article-title":"On-treatment changes in estimated GFR predict response to atorvastatin in patients with coronary heart disease: the treating to new targets (TNT) study [abstract no: TH-PO872]","volume":"19","author":"Shepherd","year":"2008","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstracts Issue","key":"10.1002\/14651858.CD007784.pub3-BIB0326|cit326","first-page":"926A","article-title":"High dose atorvastatin reduces serum uric acid: a post-hoc analysis of the Treating to New Targets (TNT) study [abstract no: PUB512]","volume":"19","author":"Shepherd","year":"2008","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD007784.pub3-BIB0327|cit327","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.amjcard.2003.09.031","article-title":"Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit?","volume":"93","author":"Waters","year":"2004","journal-title":"American Journal of Cardiology"},{"issue":"9","key":"10.1002\/14651858.CD007784.pub3-BIB0328|cit328","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1016\/j.jacc.2006.07.041","article-title":"Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (treating to new targets) study","volume":"48","author":"Waters","year":"2006","journal-title":"Journal of the American College of Cardiology"},{"issue":"6","key":"10.1002\/14651858.CD007784.pub3-BIB0329|cit329","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.pcad.2009.01.001","article-title":"Clinical insights from the treating to new targets trial","volume":"51","author":"Waters","year":"2009","journal-title":"Progress in Cardiovascular Diseases"},{"issue":"4","key":"10.1002\/14651858.CD007784.pub3-BIB0330|cit330","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1136\/hrt.2007.122325","article-title":"Beneficial effects of aggressive low-density lipoprotein cholesterol lowering in women with stable coronary heart disease in the Treating to New Targets (TNT) study","volume":"94","author":"Wenger","year":"2008","journal-title":"Heart"},{"issue":"Abstracts Issue","key":"10.1002\/14651858.CD007784.pub3-BIB0331|cit331","first-page":"307A","article-title":"Beneficial effects of pitavastatin on albuminuria and renal function in essential hypertensive patients with chronic kidney disease [abstract no: TH-PO875]","volume":"19","author":"Tokunaga","year":"2008","journal-title":"Journal of the American Society of Nephrology"},{"issue":"12","key":"10.1002\/14651858.CD007784.pub3-BIB0332|cit332","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.2337\/diacare.20.12.1891","article-title":"Reduction of albumin excretion rate in normotensive microalbuminuric type 2 diabetic patients during long-term simvastatin treatment","volume":"20","author":"Tonolo","year":"1997","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1002\/14651858.CD007784.pub3-BIB0333|cit333","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1053\/j.ajkd.2004.11.015","article-title":"First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease","volume":"45","author":"Baigent","year":"2005","journal-title":"American Journal of Kidney Diseases"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD007784.pub3-BIB0334|cit334","first-page":"437A","article-title":"Efficacy and safety of simvastatin and safety of low-dose aspirin among patients with chronic kidney disease: final results of the first UK-heart and renal protection (UK-HARP-I) study [abstract no: SA-P0841]","volume":"13","author":"Baigent","year":"2002","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Oct","key":"10.1002\/14651858.CD007784.pub3-BIB0335|cit335","first-page":"329A","article-title":"Rosuvastatin reduces high sensitivity-C reactive protein and the decline in renal function in hyperlipidemic patients with chronic kidney disease [abstract no: SA-PO134]","volume":"15","author":"Verma","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"9","key":"10.1002\/14651858.CD007784.pub3-BIB0336|cit336","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/j.amjcard.2005.06.074","article-title":"Effect of rosuvastatin on C-reactive protein and renal function in patients with chronic kidney disease","volume":"96","author":"Verma","year":"2005","journal-title":"American Journal of Cardiology"},{"issue":"4","key":"10.1002\/14651858.CD007784.pub3-BIB0337|cit337","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1081\/JDI-120039826","article-title":"Safety and efficacy of fluvastatin in hyperlipidemic patients with chronic renal disease","volume":"26","author":"Yasuda","year":"2004","journal-title":"Renal Failure"},{"issue":"8","key":"10.1002\/14651858.CD007784.pub3-BIB0338|cit338","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.clinthera.2014.06.005","article-title":"Comparison of the efficacy and safety profile of morning administration of controlled-release simvastatin versus evening administration of immediate-release simvastatin in chronic kidney disease patients with dyslipidemia","volume":"36","author":"Yi","year":"2014","journal-title":"Clinical Therapeutics"},{"issue":"3","key":"10.1002\/14651858.CD007784.pub3-BIB0339|cit339","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0168-8227(95)01138-2","article-title":"Effects of pravastatin on lipid levels, in vitro oxidizability of non-HDL lipoproteins and microalbuminuria in IDDM patients","volume":"29","author":"Zhang","year":"1995","journal-title":"Diabetes Research & Clinical Practice"},{"issue":"9","key":"10.1002\/14651858.CD007784.pub3-BIB0340|cit340","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1093\/ndt\/gfs183","article-title":"Effects of lipid-lowering treatment on platelet reactivity and platelet-leukocyte aggregation in diabetic patients without and with chronic kidney disease: a randomized trial","volume":"27","author":"Almquist","year":"2012","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD007784.pub3-BIB0341|cit341","first-page":"213A","article-title":"Effects of lipid-lowering treatment on inflammatory markers in diabetic patients with chronic kidney disease [abstract no: TH-PO506]","volume":"23","author":"Almquist","year":"2012","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD007784.pub3-BIB0342|cit342","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/eci.12230","article-title":"Lipid-lowering treatment and inflammatory mediators in diabetes and chronic kidney disease","volume":"44","author":"Almquist","year":"2014","journal-title":"European Journal of Clinical Investigation"},{"issue":"6","key":"10.1002\/14651858.CD007784.pub3-BIB0343|cit343","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1093\/ndt\/gfv337","article-title":"Effects of lipid-lowering treatment on circulating microparticles in patients with diabetes mellitus and chronic kidney disease","volume":"31","author":"Almquist","year":"2016","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD007784.pub3-BIB0344|cit344","first-page":"231A","article-title":"Effects of lipid-lowering treatment on platelet reactivity and platelet-leukocyte aggregation in diabetic patients with chronic kidney disease- a randomized trial [abstract no: TH-PO516]","volume":"22","author":"Almquist","year":"2011","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD007784.pub3-BIB0345|cit345","first-page":"25-34","article-title":"Acute effect of atorvastatin in comparison with rosuvastatin on glucose homeostasis in hypercholesteremic patients","volume":"25","author":"Almukhtar","year":"2021","journal-title":"Current Topics in Pharmacology"},{"issue":"3","key":"10.1002\/14651858.CD007784.pub3-BIB0346|cit346","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1464-5491.2004.01382.x","article-title":"Statin therapy improves brachial artery vasodilator function in patients with Type 1 diabetes and microalbuminuria","volume":"22","author":"Dogra","year":"2005","journal-title":"Diabetic Medicine"},{"issue":"6","key":"10.1002\/14651858.CD007784.pub3-BIB0347|cit347","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1053\/j.ajkd.2007.03.003","article-title":"A randomized trial of the effect of statin and fibrate therapy on arterial function in CKD","volume":"49","author":"Dogra","year":"2007","journal-title":"American Journal of Kidney Diseases"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD007784.pub3-BIB0348|cit348","first-page":"A422","article-title":"Effect of statin and fibrate therapy on vascular function in chronic kidney disease (CKD) [abstract no: 160]","volume":"10","author":"Dogra","year":"2005","journal-title":"Nephrology"},{"issue":"9","key":"10.1002\/14651858.CD007784.pub3-BIB0349|cit349","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1093\/ndt\/gfq820","article-title":"Long-term impact of mild chronic kidney disease in patients with acute coronary syndrome undergoing percutaneous coronary interventions","volume":"26","author":"Dohi","year":"2011","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"2","key":"10.1002\/14651858.CD007784.pub3-BIB0350|cit350","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.atherosclerosis.2009.12.001","article-title":"Early intensive statin treatment for six months improves long-term clinical outcomes in patients with acute coronary syndrome (Extended-ESTABLISH trial): a follow-up study","volume":"210","author":"Dohi","year":"2010","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1002\/14651858.CD007784.pub3-BIB0351|cit351","doi-asserted-by":"crossref","first-page":"42","DOI":"10.5551\/jat.5587","article-title":"Higher baseline LDL-C levels amplify the short-term benefit of early intensive statin treatment in acute coronary syndrome","volume":"18","author":"Dohi","year":"2011","journal-title":"Journal of Atherosclerosis & Thrombosis"},{"issue":"9","key":"10.1002\/14651858.CD007784.pub3-BIB0352|cit352","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1161\/01.CIR.0000140261.58966.A4","article-title":"Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH Study","volume":"110","author":"Okazaki","year":"2004","journal-title":"Circulation"},{"issue":"1","key":"10.1002\/14651858.CD007784.pub3-BIB0353|cit353","doi-asserted-by":"crossref","first-page":"66-75","DOI":"10.1111\/bdi.12973","article-title":"A double-blind, randomized, placebo-controlled pilot trial of atorvastatin for nephrogenic diabetes insipidus in lithium users","volume":"23","author":"Fotso Soh","year":"2021","journal-title":"Bipolar Disorders"},{"key":"10.1002\/14651858.CD007784.pub3-BIB0354|cit354","unstructured":"Golper TA Illingworth DR Bennett WM Correction of nephrotic hypercholesterolemia with the HMG-CoA reductase inhibitor lovastatin [abstract] 10th International Congress of Nephrology; 1987 Jul 26-31; London, UK 1987 64"},{"issue":"1","key":"10.1002\/14651858.CD007784.pub3-BIB0355|cit355","first-page":"200","article-title":"Effective and safe short term improvement in nephrotic hypercholesterolemia with the HMG CO-A reductase inhibitor mevinolin [abstract]","volume":"31","author":"Golper","year":"1987","journal-title":"Kidney International"},{"issue":"4","key":"10.1002\/14651858.CD007784.pub3-BIB0356|cit356","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S0272-6386(89)80038-1","article-title":"Lovastatin in the treatment of multifactorial hyperlipidemia associated with proteinuria","volume":"13","author":"Golper","year":"1989","journal-title":"American Journal of Kidney Diseases"},{"issue":"2","key":"10.1002\/14651858.CD007784.pub3-BIB0357|cit357","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.amjcard.2010.03.016","article-title":"Effect of ezetimibe\/atorvastatin combination on oxidized low density lipoprotein cholesterol in patients with coronary artery disease or coronary artery disease equivalent","volume":"106","author":"Azar","year":"2010","journal-title":"American Journal of Cardiology"},{"issue":"2","key":"10.1002\/14651858.CD007784.pub3-BIB0358|cit358","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.ahj.2014.05.004","article-title":"Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study population","volume":"168","author":"Blazing","year":"2014","journal-title":"American Heart Journal"},{"issue":"13","key":"10.1002\/14651858.CD007784.pub3-BIB0359|cit359","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1161\/CIRCULATIONAHA.115.018381","article-title":"Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT","volume":"132","author":"Bohula","year":"2015","journal-title":"Circulation"},{"issue":"8","key":"10.1002\/14651858.CD007784.pub3-BIB0360|cit360","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.jacc.2016.11.070","article-title":"Atherothrombotic risk stratification and ezetimibe for secondary prevention","volume":"69","author":"Bohula","year":"2017","journal-title":"Journal of the American College of Cardiology"},{"issue":"25","key":"10.1002\/14651858.CD007784.pub3-BIB0361|cit361","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1161\/CIRCULATIONAHA.117.029095","article-title":"Prevention of stroke with the addition of ezetimibe to statin therapy in patients with acute coronary syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)","volume":"136","author":"Bohula","year":"2017","journal-title":"Circulation"},{"issue":"25","key":"10.1002\/14651858.CD007784.pub3-BIB0362|cit362","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD007784.pub3-BIB0363|cit363","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.ahj.2008.07.023","article-title":"Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe\/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes","volume":"156","author":"Cannon","year":"2008","journal-title":"American Heart Journal"},{"issue":"15","key":"10.1002\/14651858.CD007784.pub3-BIB0364|cit364","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1161\/CIRCULATIONAHA.117.030950","article-title":"Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)","volume":"137","author":"Giugliano","year":"2018","journal-title":"Circulation"},{"issue":"5","key":"10.1002\/14651858.CD007784.pub3-BIB0365|cit365","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1001\/jamacardio.2017.0083","article-title":"Long-term safety and efficacy of achieving very low levels of low-density lipoprotein cholesterol: a prespecified analysis of the IMPROVE-IT trial","volume":"2","author":"Giugliano","year":"2017","journal-title":"JAMA Cardiology"},{"issue":"11","key":"10.1002\/14651858.CD007784.pub3-BIB0366|cit366","doi-asserted-by":"crossref","first-page":"e006901","DOI":"10.1161\/JAHA.117.006901","article-title":"Efficacy and safety of adding ezetimibe to statin therapy among women and men: insight from IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)","volume":"6","author":"Kato","year":"2017","journal-title":"Journal of the American Heart Association"},{"issue":"4","key":"10.1002\/14651858.CD007784.pub3-BIB0367|cit367","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jacc.2015.10.077","article-title":"Reduction in total cardiovascular events with ezetimibe\/simvastatin post-acute coronary syndrome: the IMPROVE-IT Trial","volume":"67","author":"Murphy","year":"2016","journal-title":"Journal of the American College of Cardiology"},{"issue":"13","key":"10.1002\/14651858.CD007784.pub3-BIB0368|cit368","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1056\/NEJMsa0806603","article-title":"Analyses of cancer data from three ezetimibe trials","volume":"359","author":"Peto","year":"2008","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD007784.pub3-BIB0369|cit369","first-page":"e003201","article-title":"Impact of ezetimibe on the rate of cardiovascular-related hospitalizations and associated costs among patients with a recent acute coronary syndrome: results from the IMPROVE-IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)","volume":"10","author":"Pokharel","year":"2017","journal-title":"Circulation: Cardiovascular Quality & Outcomes"},{"key":"10.1002\/14651858.CD007784.pub3-BIB0370|cit370","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.ijcard.2018.05.087","article-title":"The nonalcoholic fatty liver disease (NAFLD) fibrosis score, cardiovascular risk stratification and a strategy for secondary prevention with ezetimibe","volume":"270","author":"Simon","year":"2018","journal-title":"International Journal of Cardiology"},{"issue":"10","key":"10.1002\/14651858.CD007784.pub3-BIB0371|cit371","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1681\/ASN.2016090957","article-title":"Benefit of ezetimibe added to simvastatin in reduced kidney function","volume":"28","author":"Stanifer","year":"2017","journal-title":"Journal of the American Society of Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD007784.pub3-BIB0372|cit372","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1007\/s10157-013-0904-7","article-title":"Effects of atorvastatin and ezetimibe on endothelial function in dyslipidemic patients with chronic kidney disease","volume":"18","author":"Ishimitsu","year":"2014","journal-title":"Clinical & Experimental Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD007784.pub3-BIB0373|cit373","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/1074248412445506","article-title":"Effects of rosuvastatin with or without ezetimibe on clinical outcomes in patients undergoing elective vascular surgery: results of a pilot study","volume":"18","author":"Kouvelos","year":"2013","journal-title":"Journal of Cardiovascular Pharmacology & Therapeutics"},{"issue":"2","key":"10.1002\/14651858.CD007784.pub3-BIB0374|cit374","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1177\/0003319713519492","article-title":"The effect of adding ezetimibe to rosuvastatin on renal function in patients undergoing elective vascular surgery","volume":"66","author":"Kouvelos","year":"2015","journal-title":"Angiology"},{"key":"10.1002\/14651858.CD007784.pub3-BIB0375|cit375","first-page":"1610","article-title":"HMG CoA reductase inhibitors - effects on endothelial function and lipoprotein levels in children with chronic kidney disease [abstract no: P053]","volume":"23","author":"Mackie","year":"2008","journal-title":"Pediatric Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD007784.pub3-BIB0376|cit376","first-page":"205-14","article-title":"Preventive effects of nicorandil and atorvastatin in contrastinduced nephropathy in patients with renal dysfunction undergoing coronary artery angiography: a double blind, randomized, controlled clinical trial","volume":"17","author":"Mohammadi Kebar","year":"2023","journal-title":"Iranian Journal of Kidney Diseases"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD007784.pub3-BIB0377|cit377","first-page":"204A","article-title":"Effect of atorvastatin on renal NO availability and tubular function in patients with stage II-III chronic kidney disease and type 2 diabetes [abstract no: TH-PO447]","volume":"24","author":"Mose","year":"2013","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD007784.pub3-BIB0378|cit378","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3109\/00365513.2013.855942","article-title":"Effect of atorvastatin on renal NO availability and tubular function in patients with stage II-III chronic kidney disease and type 2 diabetes","volume":"74","author":"Mose","year":"2014","journal-title":"Scandinavian Journal of Clinical & Laboratory Investigation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD007784.pub3-BIB0379|cit379","first-page":"i367","article-title":"Effect of atorvastatin on renal NO availability and tubular function in patients with non-diabetic, stage II-III chronic kidney disease [abstract no: MP219]","volume":"28","author":"Larsen","year":"2013","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD007784.pub3-BIB0380|cit380","first-page":"673A","article-title":"Increased NO activity during statin treatment in patients with non-diabetic nephropathy [abstract no: SA-PO169]","volume":"23","author":"Mose","year":"2012","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD007784.pub3-BIB0381|cit381","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/bcp.12390","article-title":"Effects of atorvastatin on systemic and renal NO dependency in patients with non-diabetic stage II-III chronic kidney disease","volume":"78","author":"Mose","year":"2014","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD007784.pub3-BIB0382|cit382","unstructured":"Lan DT Lipid-lowering therapies in Vietnamese chronic kidney disease population (VietCKD) www.clinicaltrials.gov\/show\/NCT03543774"},{"issue":"2","key":"10.1002\/14651858.CD007784.pub3-BIB0383|cit383","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.atherosclerosis.2006.12.020","article-title":"Rosuvastatin improves basal nitric oxide activity of the renal vasculature in patients with hypercholesterolemia","volume":"196","author":"Ott","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1002\/14651858.CD007784.pub3-BIB0384|cit384","unstructured":"Impact of ATOrvastatin REload on the Prevention of Contrast-INduced Nephropathy in patients on Chronic Statin Therapy: a prospective randomized trial (ATORE-CIN) https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=PACTR202110707328144"},{"issue":"7","key":"10.1002\/14651858.CD007784.pub3-BIB0385|cit385","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1177\/0091270009350627","article-title":"Acute effects of atorvastatin on glomerular filtration rate, tubular function, blood pressure, and vasoactive hormones in patients with type 2 diabetes","volume":"50","author":"Paulsen","year":"2010","journal-title":"Journal of Clinical Pharmacology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD007784.pub3-BIB0386|cit386","first-page":"359","article-title":"Evidence for the lipid independent effects of statins on endothelial function [abstract no: T245]","volume":"18","author":"Schmieder","year":"2003","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"11","key":"10.1002\/14651858.CD007784.pub3-BIB0387|cit387","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1097\/HJH.0b013e32834ae3c7","article-title":"Atorvastatin reduces sympathetic activity in patients with chronic kidney disease","volume":"29","author":"Siddiqi","year":"2011","journal-title":"Journal of Hypertension"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD007784.pub3-BIB0388|cit388","first-page":"672A","article-title":"Comparative efficacy and adverse effects of the addition of ezetimibe to statin versus statin titration in chronic disease (CKD) patients [abstract no: SA-PO161]","volume":"23","author":"Suzuki","year":"2012","journal-title":"Journal of the American Society of Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD007784.pub3-BIB0389|cit389","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1177\/1753944713513222","article-title":"Comparative efficacy and adverse effects of the addition of ezetimibe to statin versus statin titration in chronic kidney disease patients","volume":"7","author":"Suzuki","year":"2013","journal-title":"Therapeutic Advances in Cardiovascular Disease"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD007784.pub3-BIB0390|cit390","first-page":"iv390","article-title":"Effects of high doses of atorvastatin (ATO) on renal dynamics and vascular reactivity in patients with chronic renal failure (CRF) [abstract no: MP272]","volume":"21","author":"Torraca","year":"2006","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"3","key":"10.1002\/14651858.CD007784.pub3-BIB0391|cit391","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1053\/j.ajkd.2005.11.018","article-title":"The second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: a randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD","volume":"47","author":"Landray","year":"2006","journal-title":"American Journal of Kidney Diseases"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD007784.pub3-BIB0392|cit392","first-page":"119","article-title":"Biochemical safety and efficacy of co-administration of ezetimibe and simvastatin among patients with chronic kidney disease: the second UK-heart and renal protection (UK-HARP-II) study [abstract no: M383]","volume":"18","author":"Landray","year":"2003","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"11","key":"10.1002\/14651858.CD007784.pub3-BIB0393|cit393","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1093\/ndt\/16.11.2152","article-title":"Effect of simvastatin on renal function in autosomal dominant polycystic kidney disease","volume":"16","author":"Dijk","year":"2001","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD007784.pub3-BIB0394|cit394","first-page":"i274","article-title":"The role of short-term, high-dose atorvastatin for prevention of contrast-induced acute kidney injury (CI-AKI) in patients with cardiovascular diseases undergoing computed tomography with intravenous contrast administration","volume":"36","author":"Vasin","year":"2021","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"9","key":"10.1002\/14651858.CD007784.pub3-BIB0395|cit395","doi-asserted-by":"crossref","first-page":"1455-63","DOI":"10.1253\/circj.CJ-21-0869","article-title":"Prevention of contrast-induced nephropathy after cardiovascular catheterization and intervention with high-dose strong statin therapy in Japan - The PREVENT CINC-J Study","volume":"86","author":"Watanabe","year":"2022","journal-title":"Circulation Journal"},{"issue":"8","key":"10.1002\/14651858.CD007784.pub3-BIB0396|cit396","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.clinthera.2013.06.013","article-title":"A randomized, double-blind study of fenofibric acid plus rosuvastatin compared with rosuvastatin alone in stage 3 chronic kidney disease [Erratum appears in Clin Ther. 2013 Nov;35(11):1862]","volume":"35","author":"Weinstein","year":"2013","journal-title":"Clinical Therapeutics"},{"issue":"1","key":"10.1002\/14651858.CD007784.pub3-BIB0397|cit397","first-page":"39","article-title":"Association of high-density lipoprotein cholesterol with improvement of endothelial dysfunction recovery in renovascular disease","volume":"9","author":"Yasmeen","year":"2015","journal-title":"Iranian Journal of Kidney Diseases"},{"issue":"6","key":"10.1002\/14651858.CD007784.pub3-BIB0398|cit398","doi-asserted-by":"crossref","first-page":"680","DOI":"10.3109\/0886022X.2010.486493","article-title":"Effects of atorvastatin versus probucol on low-density lipoprotein subtype distribution and renal function in hyperlipidemic patients with nondiabetic nephropathy","volume":"32","author":"Yasuda","year":"2010","journal-title":"Renal Failure"},{"issue":"19","key":"10.1002\/14651858.CD007784.pub3-BIB0399|cit399","doi-asserted-by":"crossref","first-page":"e027516","DOI":"10.1161\/JAHA.122.027516","article-title":"Association of low-density lipoprotein cholesterol levels during statin treatment with cardiovascular and renal outcomes in patients with moderate chronic kidney disease","volume":"11","author":"Yen","year":"2022","journal-title":"Journal of the American Heart Association"},{"issue":"4","key":"10.1002\/14651858.CD007784.pub3-BIB0400|cit400","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1007\/s00726-012-1223-0","article-title":"Oxidative stress improvement is associated with increased levels of taurine in CKD patients undergoing lipid-lowering therapy","volume":"43","author":"Zinellu","year":"2012","journal-title":"Amino Acids"},{"issue":"2","key":"10.1002\/14651858.CD007784.pub3-BIB0401|cit401","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.numecd.2014.11.004","article-title":"Impact of cholesterol lowering treatment on plasma kynurenine and tryptophan concentrations in chronic kidney disease: relationship with oxidative stress improvement","volume":"25","author":"Zinellu","year":"2015","journal-title":"Nutrition Metabolism & Cardiovascular Diseases"},{"key":"10.1002\/14651858.CD007784.pub3-BIB0402|cit402","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jpba.2016.07.025","article-title":"Effect of cholesterol lowering treatment on plasma markers of endothelial dysfunction in chronic kidney disease","volume":"129","author":"Zinellu","year":"2016","journal-title":"Journal of Pharmaceutical & Biomedical Analysis"},{"issue":"1","key":"10.1002\/14651858.CD007784.pub3-BIB0403|cit403","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ejps.2012.05.006","article-title":"LDL S-homocysteinylation decrease in chronic kidney disease patients undergone lipid lowering therapy","volume":"47","author":"Zinellu","year":"2012","journal-title":"European Journal of Pharmaceutical Sciences"},{"issue":"9","key":"10.1002\/14651858.CD007784.pub3-BIB0404|cit404","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.numecd.2017.06.011","article-title":"Cholesterol lowering treatment restores blood global DNA methylation in chronic kidney disease (CKD) patients","volume":"27","author":"Zinellu","year":"2017","journal-title":"Nutrition Metabolism & Cardiovascular Diseases"},{"key":"10.1002\/14651858.CD007784.pub3-BIB0405|cit405","unstructured":"Agharazii M The renal protective effects of low-dose and high-dose atorvastatin in patients with glomerular disease and proteinuria: a randomized controlled double blinded study clinicaltrials gov\/ct2\/show\/NCT00768638"},{"key":"10.1002\/14651858.CD007784.pub3-BIB0406|cit406","unstructured":"An WS Effect of pitavastatin on erythrocyte membrane fatty acid contents in patients with chronic kidney disease clinicaltrials.gov\/show\/NCT02863185"},{"key":"10.1002\/14651858.CD007784.pub3-BIB0407|cit407","unstructured":"Atorvastatin and alkali therapy in patients with autosomal dominant polycystic kidney disease https:\/\/clinicaltrials.gov\/show\/NCT05870007"},{"issue":"9493","key":"10.1002\/14651858.CD007784.pub3-BIB0408|cit408","first-page":"1267","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins [Erratum in: Lancet. 2005 Oct 15-21;366(9494):1358] [Erratum in: Lancet. 2008 Jun 21;371(9630):2084]","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD007784.pub3-BIB0409|cit409","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1001\/jamacardio.2016.4652","article-title":"Absolute rates of heart failure, coronary heart disease, and stroke in chronic kidney disease: an analysis of 3 community-based cohort studies","volume":"2","author":"Bansal","year":"2017","journal-title":"JAMA Cardiology"},{"issue":"20","key":"10.1002\/14651858.CD007784.pub3-BIB0410|cit410","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1001\/jama.2010.651","article-title":"Reporting and interpretation of randomized controlled trials with statistically nonsignificant results for primary outcomes","volume":"303","author":"Boutron","year":"2010","journal-title":"JAMA"},{"issue":"17","key":"10.1002\/14651858.CD007784.pub3-BIB0411|cit411","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1001\/jama.295.17.2046","article-title":"Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes: a meta-analysis of randomized controlled trials","volume":"295","author":"Briel","year":"2006","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD007784.pub3-BIB0412|cit412","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1681\/ASN.2004110958","article-title":"Are 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors renoprotective?","volume":"16 Suppl 1","author":"Campese","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD007784.pub3-BIB0413|cit413","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/nep.12052","article-title":"KHA-CARI Guideline: Early chronic kidney disease: Detection, prevention and management","volume":"18","author":"Johnson","year":"2013","journal-title":"Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD007784.pub3-BIB0414|cit414","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s11606-010-1511-x","article-title":"Chronic kidney disease and the risk of end-stage renal disease versus death","volume":"26","author":"Dalrymple","year":"2011","journal-title":"Journal General Internal Medicine"},{"key":"10.1002\/14651858.CD007784.pub3-BIB0415|cit415","doi-asserted-by":"crossref","first-page":"S114","DOI":"10.1046\/j.1523-1755.2001.59780114.x","article-title":"Role of oxidized low-density lipoprotein in the atherosclerosis of uremia","volume":"78","author":"Drueke","year":"2001","journal-title":"Kidney International - Supplement"},{"issue":"5 Suppl 3","key":"10.1002\/14651858.CD007784.pub3-BIB0416|cit416","doi-asserted-by":"crossref","first-page":"S112","DOI":"10.1053\/ajkd.1998.v32.pm9820470","article-title":"Clinical epidemiology of cardiovascular disease in chronic renal disease","volume":"32","author":"Foley","year":"1998","journal-title":"American Journal of Kidney Diseases"},{"issue":"9","key":"10.1002\/14651858.CD007784.pub3-BIB0417|cit417","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.disamonth.2015.07.005","article-title":"Cardiovascular disease and chronic kidney disease","volume":"61","author":"Gargiulo","year":"2015","journal-title":"Disease-a-Month"},{"issue":"10225","key":"10.1002\/14651858.CD007784.pub3-BIB0418|cit418","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","article-title":"Global, regional, and national burden of chronic kidney disease, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"395","year":"2020","journal-title":"Lancet"},{"issue":"13","key":"10.1002\/14651858.CD007784.pub3-BIB0419|cit419","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization","volume":"351","author":"Go","year":"2004","journal-title":"New England Journal of Medicine"},{"issue":"7650","key":"10.1002\/14651858.CD007784.pub3-BIB0420|cit420","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD007784.pub3-BIB0421|cit421","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"20","key":"10.1002\/14651858.CD007784.pub3-BIB0422|cit422","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1002\/sim.2380","article-title":"A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints","volume":"25","author":"Harbord","year":"2006","journal-title":"Statistics in Medicine"},{"issue":"3","key":"10.1002\/14651858.CD007784.pub3-BIB0423|cit423","first-page":"263","article-title":"Assessment of the efficiency of treatment of dyslipidemia in renal outpatients","volume":"15","author":"Harris","year":"2002","journal-title":"Journal of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD007784.pub3-BIB0424|cit424","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1111\/j.1523-1755.2002.kid571.x","article-title":"Mild renal insufficiency is associated with increased cardiovascular mortality: the Hoorn Study","volume":"62","author":"Henry","year":"2002","journal-title":"Kidney International"},{"issue":"10","key":"10.1002\/14651858.CD007784.pub3-BIB0425|cit425","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S2213-8587(16)30156-5","article-title":"Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials","volume":"4","author":"Herrington","year":"2016","journal-title":"The Lancet Diabetes & Endocrinology"},{"issue":"7414","key":"10.1002\/14651858.CD007784.pub3-BIB0426|cit426","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD007784.pub3-BIB0427|cit427","unstructured":"Higgins JP Thomas J Chandler J Cumpston M Li T Page MJ Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022 Available from www.training.cochrane.org\/handbook"},{"issue":"3","key":"10.1002\/14651858.CD007784.pub3-BIB0428|cit428","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1161\/01.RES.62.2.367","article-title":"Pharmacologic treatment of hyperlipidemia reduces glomerular injury in rat 5\/6 nephrectomy model of chronic renal failure","volume":"62","author":"Kasiske","year":"1988","journal-title":"Circulation Research"},{"issue":"1","key":"10.1002\/14651858.CD007784.pub3-BIB0429|cit429","first-page":"1","article-title":"KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease","volume":"3","author":"Levin","year":"2013","journal-title":"Kidney International Supplments"},{"key":"10.1002\/14651858.CD007784.pub3-BIB0430|cit430","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/kisup.2013.27","article-title":"KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease","volume":"3","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Lipid Work Group","year":"2013","journal-title":"Kidney International Supplement"},{"key":"10.1002\/14651858.CD007784.pub3-BIB0431|cit431","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1046\/j.1523-1755.2000.07503.x","article-title":"The role of lipids in renal disease: future challenges","volume":"75","author":"Keane","year":"2000","journal-title":"Kidney International - Supplement"},{"issue":"4A","key":"10.1002\/14651858.CD007784.pub3-BIB0432|cit432","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0002-9149(02)03268-X","article-title":"Effects of statins on inflammation in patients with acute and chronic coronary syndromes","volume":"91","author":"Kinlay","year":"2003","journal-title":"American Journal of Cardiology"},{"key":"10.1002\/14651858.CD007784.pub3-BIB0433|cit433","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"issue":"19","key":"10.1002\/14651858.CD007784.pub3-BIB0434|cit434","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199811053391902","article-title":"Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels","volume":"339","year":"1998","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD007784.pub3-BIB0435|cit435","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0735-1097(02)02663-3","article-title":"Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community","volume":"41","author":"Manjunath","year":"2003","journal-title":"Journal of American College of Cardiology"},{"issue":"9","key":"10.1002\/14651858.CD007784.pub3-BIB0436|cit436","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1093\/ndt\/16.9.1738","article-title":"Statins: effects beyond cholesterol lowering","volume":"16","author":"Massy","year":"2001","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"10","key":"10.1002\/14651858.CD007784.pub3-BIB0437|cit437","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1093\/eurheartj\/ehi880","article-title":"Chronic kidney disease and risk of incident myocardial infarction and all-cause and cardiovascular disease mortality in middle-aged men and women from the general population","volume":"27","author":"Meisigner","year":"2006","journal-title":"European Heart Journal"},{"issue":"2","key":"10.1002\/14651858.CD007784.pub3-BIB0438|cit438","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1681\/ASN.2004080656","article-title":"Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study","volume":"16","author":"Muntner","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD007784.pub3-BIB0439|cit439","unstructured":"National Institute for Health and Clinical Excellence Cardiovascular disease: risk assessment and reduction, including lipid modification https:\/\/www.nice.org.uk\/guidance\/cg181"},{"issue":"9","key":"10.1002\/14651858.CD007784.pub3-BIB0440|cit440","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004289.pub5","article-title":"HMG CoA reductase inhibitors (statins) for dialysis patients","author":"Palmer","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD007784.pub3-BIB0441|cit441","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005019.pub4","article-title":"HMG CoA reductase inhibitors (statins) for kidney transplant recipients","author":"Palmer","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD007784.pub3-BIB0442|cit442","unstructured":"R Core Team R: A language and environment for statistical computing R Foundation for Statistical Computing 2013 Vienna, Austria"},{"issue":"10","key":"10.1002\/14651858.CD007784.pub3-BIB0443|cit443","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/j.jacc.2005.05.085","article-title":"Pleiotropic effects of statins: benefit beyond cholesterol reduction. A meta-regression analysis","volume":"46","author":"Robinson","year":"2005","journal-title":"Journal of the American College of Cardiology"},{"issue":"14","key":"10.1002\/14651858.CD007784.pub3-BIB0444|cit444","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","article-title":"The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels","volume":"335","author":"Sacks","year":"1996","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"10.1002\/14651858.CD007784.pub3-BIB0445|cit445","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1681\/ASN.V1482084","article-title":"Cholesterol and the risk of renal dysfunction in apparently healthy men","volume":"14","author":"Schaeffner","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD007784.pub3-BIB0446|cit446","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing \u2018Summary of findings\u2019 tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022 www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD007784.pub3-BIB0447|cit447","unstructured":"Sch\u00fcnemann HJ Vist GE Higgins JP Santesso N Deeks JJ Glasziou P Chapter 15: Interpreting results and drawing conclusions. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022 Available from www.training.cochrane.org\/handbook"},{"issue":"20","key":"10.1002\/14651858.CD007784.pub3-BIB0448|cit448","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","article-title":"Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group","volume":"333","author":"Shepherd","year":"1995","journal-title":"New England Journal of Medicine"},{"issue":"14","key":"10.1002\/14651858.CD007784.pub3-BIB0449|cit449","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1001\/jama.293.14.1737","article-title":"Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors","volume":"293","author":"Shlipak","year":"2005","journal-title":"JAMA"},{"issue":"6","key":"10.1002\/14651858.CD007784.pub3-BIB0450|cit450","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/clc.23347","article-title":"Trends in prevalence of guideline-based use of lipid-lowering therapy in a large health system","volume":"43","author":"Sidebottom","year":"2020","journal-title":"Clinical Cardiology"},{"issue":"12","key":"10.1002\/14651858.CD007784.pub3-BIB0451|cit451","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1345\/aph.10124","article-title":"Beneficial effects of statins in coronary artery disease--beyond lowering cholesterol","volume":"34","author":"Sotiriou","year":"2000","journal-title":"Annals of Pharmacotherapy"},{"key":"10.1002\/14651858.CD007784.pub3-BIB0452|cit452","volume-title":"StatPearls - Ezetimibe [Internet]","year":"2023"},{"issue":"3 (Suppl 1)","key":"10.1002\/14651858.CD007784.pub3-BIB0453|cit453","doi-asserted-by":"publisher","first-page":"S79","DOI":"10.1053\/j.ajkd.2018.12.004","article-title":"US Renal Data System 2018 Annual Data Report. Chapter 4. Cardiovascular disease in patients with CKD","volume":"73","year":"2019","journal-title":"American Journal of Kidney Diseases"},{"issue":"2","key":"10.1002\/14651858.CD007784.pub3-BIB0454|cit454","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007784","article-title":"HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis","author":"Navaneethan","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD007784.pub3-BIB0455|cit455","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007784.pub2","article-title":"HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis","author":"Palmer","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7645","key":"10.1002\/14651858.CD007784.pub3-BIB0456|cit456","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1136\/bmj.39472.580984.AE","article-title":"Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials","volume":"336","author":"Strippoli","year":"2008","journal-title":"BMJ"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T14:51:14Z","timestamp":1729263074000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD007784.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Kidney and Transplant Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,11,29]]},"references-count":456,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,12]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd007784.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,29]]}}}